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For the treatment of full-thickness skin defects, autologous split-thickness skin grafting is the 
gold standard. However, the outcome of this approach may be impaired by scarring, wound 
contraction, or the lack of vascularization within the wound bed. To counteract these 
problems, bioengineered off-the-shelf matrices, such as Integra® Matrix Wound Dressing 
(MWD), have been introduced over the past years. This collagen-glycosaminoglycan matrix 
with a silicone pseudo-epidermis is first implanted into the debrided wound bed. Only after a 
sufficient vascularization, the silicone layer is removed and the matrix can be covered with a 
split-thickness skin graft. Noteworthy, the ingrowth of blood vessels into the matrix requires 
up to 3 weeks. Since wound infection is a threat throughout this time, strategies are needed 
to improve the vascularization of the matrix. Prevascularization, which aims for the creation 
of microvascular networks within the matrix prior to its implantation, is such a strategy. 
Although the seeding of matrices with stem cells showed positive results in the creation of 
preformed networks, a time-consuming in vitro cultivation is necessary to generate the 
needed number of cells. Moreover, stem cells need too much time to vascularize the entire 
matrix. To overcome this problem, the seeding of matrices with adipose tissue-derived 
microvascular fragments (ad-MVF) has recently been introduced as a promising strategy. 
Ad-MVF can easily be isolated from adipose tissue and, unlike single cells, already represent 
fully functional blood vessel segments that rapidly reassemble into new microvascular 
networks within seeded matrices. However, although experimental studies indicate the 
benefits of ad-MVF as prevascularization units, many questions have to be clarified to allow 
a successful transfer of this novel approach into clinical practice, as outlined and analyzed in 
the present doctoral thesis. 
 
For all in vitro and in vivo parts of this thesis, green fluorescent protein (GFP)+ C57BL/6 mice 
were used as ad-MVF donor animals. The tissue of these animals appears green under blue 
light excitation, enabling the identification of ad-MVF after their transplantation into GFP- 
C57BL/6 recipient mice. Non-seeded and ad-MVF- or stromal vascular fraction (SVF)-
seeded Integra® matrices were implanted into full-thickness skin defects within mouse dorsal 
skinfold chambers to analyze their vascularization, incorporation, oxygenation, and 
epithelialization by means of intravital fluorescence microscopy, photoacoustic imaging, 
histology, and immunohistochemistry over an observation period of 2 weeks. 
 
The aim of a first set of experiments was to clarify whether the volumes of epididymal 
adipose tissue and/or the numbers of ad-MVF depend on the age of the animal. For this 
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purpose, 7 - 12 months old GFP+ C57BL/6 donor mice were used for harvesting their 
epididymal fat tissue and subsequent ad-MVF isolations. It was found that a comparable 
volume of ~ 1.4 mL fat tissue can be harvested from animals ranging between 7 - 12 months. 
Furthermore, a comparable number of ~ 40.000 ad-MVF/mL adipose tissue could be isolated 
from these mice. The isolated ad-MVF exhibited an average length of ~ 38 µm and a viability 
of > 90 %. This indicates that all mice of the analyzed age range can be used for a highly 
standardized isolation of ad-MVF. 
 
In a second set of experiments it was hypothesized that the seeding of ad-MVF on a 
flowable matrix, which allows a more homogeneous distribution, may result in a faster matrix 
vascularization and incorporation when compared to MWD. For this purpose, MWD as well 
as samples of Integra® Flowable Wound Matrix (FWM) were seeded with identical numbers 
of ad-MVF. Of interest, FWM exhibited a more homogeneous distribution of individual ad-
MVF when compared to MWD. However, when implanted into full-thickness skin defects 
within GFP- C57BL/6 recipient mice, this resulted in an increased distance between individual 
ad-MVF, leading to a prolonged ad-MVF interconnection time as well as a reduced matrix 
vascularization and incorporation in vivo. These results indicate that MWD is more suitable 
for the treatment of rather large wounds, while FWM may be particularly used for the 
treatment of small wounds and wounds with irregular geometries which are hardly to access.  
 
In a third set of experiments it was hypothesized that the seeding density of ad-MVF is a 
crucial determinant for an adequate vascularization and incorporation of seeded matrices. 
For this purpose, MWD was seeded with three different densities of ad-MVF. The results 
indicate that a minimum density of ~ 80,000 ad-MVF/cm2 is required to guarantee a sufficient 
vascularization and incorporation of implanted MWD in vivo. Under clinical conditions, this 
may be particularly relevant for the treatment of patients with extensive skin defects and/or 
limited availability of adipose tissue.  
 
Besides the novel approach of ad-MVF prevascularization, the seeding of matrices with 
vessel-forming single cells of the SVF is a frequently applied strategy. In a fourth set of 
experiments it was hypothesized that the ad-MVF-based prevascularization of MWD is 
superior to the conventional SVF-based approach. While both ad-MVF and SVF isolates 
contained a comparable fraction of endothelial cells, perivascular cells, adipocytes, and stem 
cells, ad-MVF exhibited a significantly higher viability after their isolation. It was further 
shown that SVF-seeded MWD exhibited a reduced vascularization and incorporation when 
compared to ad-MVF-seeded MWD in vivo. These novel findings indicate that ad-MVF are 
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highly potent vascularization units that may be even superior to SVF single cells in future 
tissue engineering applications. 
 
In a fifth set of experiments it was hypothesized that the anti-angiogenic properties of low 
molecular weight heparins (LMWH), such as enoxaparin (enox), prevent the reassembly of 
seeded ad-MVF into new microvascular networks. It was further hypothesized that the anti-
coagulative properties of enox may increase the bleeding risk during network formation 
within implanted MWD. To test these hypotheses, ad-MVF were isolated from enox- and 
vehicle-treated GFP+ C57BL/6 donor mice, seeded onto MWD and implanted into enox- and 
vehicle-treated GFP- recipient animals. Intravital fluorescence microscopic, histological, and 
immunohistochemical analyses revealed that enox does neither inhibit the reassembly of ad-
MVF nor promotes implant-induced hemorrhage formation. These novel findings 
demonstrate that the seeding of MWD matrices with ad-MVF as prevascularization units may 
also be applied during thromboprophylactic therapy without any concern.  




Obwohl die Deckung dermaler Wunden mittels autologer Spalthauttransplantate zur  
klinischen Standardbehandlung zählt, kann der Erfolg dieser Methode durch Komplikationen 
wie Narbenbildung, Wundkontraktionen oder eine ausbleibende Vaskularisierung des 
Wundbetts gefährdet werden. Um diese Probleme zu vermeiden, wurden in den letzten 
Jahren biosynthetische Matrices, wie beispielsweise Integra® Matrix Wound Dressing 
(MWD), entwickelt. MWD ist eine Kollagen-Glykosaminoglykan-Matrix, welche mit einer 
Pseudo-Epidermis aus Silikon bedeckt ist, um die Austrocknung der Wunde zu verhindern. 
Erst nach ausreichender Vaskularisierung der Matrix kann die Silikonschicht abgenommen 
werden und eine Deckung mit Spalthaut erfolgen. Da die Vaskularisierung bis zu 3 Wochen 
dauern kann und in diesem Zeitraum ein erhöhtes Infektionsrisiko besteht, müssen 
unbedingt neue Strategien zur Beschleunigung der Vaskularisierung solcher Matrices 
entwickelt werden. Ein solcher Ansatz ist die Prävaskularisierung, eine Methode, bei der 
mikrovaskuläre Netzwerke in einer Matrix vor deren Implantation generiert werden. Auch 
wenn die Besiedlung von Matrices mit Stammzellen bereits positive Ergebnisse bei der 
Herstellung prävaskularisierter Netzwerke gezeigt hat, sind dabei zeitaufwändige in vitro 
Kultivierungen unabdingbar, um eine ausreichende Zellzahl zu erhalten. Darüber hinaus 
benötigen Stammzellen zu viel Zeit, bis sie sich in der gesamten Matrix zu neuen 
Blutgefäßen entwickelt haben. Um diese Probleme zu vermeiden, wurde kürzlich die 
Prävaskularisierung von Matrices mit mikrovaskulären Fragmenten (ad-MVF) aus 
Fettgewebe als neue Strategie beschrieben. Ad-MVF können in großen Mengen durch 
enzymatische Digestion von Fettgewebe gewonnen werden und stellen, im Gegensatz zu 
Einzelzellen, bereits intakte Gefäßsegmente dar, welche sich innerhalb einer Matrix nur noch 
zusammenlagern müssen, um vollständige Netzwerke auszubilden. Auch wenn 
experimentelle Studien den Einsatz von ad-MVF als Prävaskularisierungseinheiten bereits 
als vielversprechend beschreiben, müssen noch wesentliche Fragen beantwortet werden, 
um diesen Ansatz erfolgreich in die Klinik einzuführen. 
 
Für alle in vitro und in vivo Versuche der vorliegenden Arbeit wurden green fluorescent 
protein (GFP)+ C57BL/6 Spendermäuse zur Fettgewinnung und Isolation von ad-MVF 
verwendet. Das Gewebe dieser Tiere erscheint unter Anregung mit blauem Licht grün und 
ermöglicht so die Identifikation von ad-MVF nach Implantation in GFP- Empfängertiere. 
Unbesiedelte und ad-MVF- oder stromal vascular fraction (SVF)-besiedelte Integra® Matrices 
wurden in Vollhautdefekte innerhalb von Rückenhautkammern implantiert und anschließend 
deren Vaskularisierung, Inkorporation, Oxygenierung und Epithelialisierung mittels 
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intravitaler Fluoreszenzmikroskopie, photoakustischer Bildgebung, Histologie und 
Immunhistochemie über einen Zeitraum von 2 Wochen analysiert.  
 
In einem ersten experimentellen Teil wurde die Hypothese geprüft, ob die Menge an 
epididymalem Fettgewebe oder die Anzahl isolierbarer ad-MVF abhängig vom Alter des 
Spendertieres sind. Zu diesem Zweck wurden 7 - 12 Monate alte GFP+ C57BL/6 Mäuse 
verwendet, um deren epididymales Fett zu entnehmen und ad-MVF zu isolieren. Dabei 
konnte gezeigt werden, dass aus allen Spendermäusen ein vergleichbares Volumen von ~ 
1,4 ml Fettgewebe gewonnen werden kann. Zusätzlich war es bei einer Viabilität von > 90 % 
möglich, aus allen 7 - 12 Monate alten Tieren ~ 40,000 ad-MVF/ml Fettgewebe zu isolieren, 
wobei diese eine mittlere Länge von ~ 38 µm aufwiesen. Diese Ergebnisse zeigen, dass aus 
7 - 12 Monate alten Spendermäusen eine standardisierte Isolation von ad-MVF möglich ist. 
 
In einem zweiten experimentellen Teil wurde die Hypothese geprüft, ob eine homogenere 
Verteilung von ad-MVF in einer fließfähigen Matrix zu einer verbesserten in vivo 
Vaskularisierung führt. Hierzu wurden sowohl MWD als auch Einzelproben der Integra® 
Flowable Wound Matrix (FWM) mit einer identischen Anzahl von ad-MVF besiedelt. Auf 
diese Weise konnte gezeigt werden, dass FWM eine homogenere Verteilung von ad-MVF 
ermöglicht. Dies ging allerdings mit einer erhöhten Distanz einzelner ad-MVF zueinander 
einher und führte zu einer verlangsamten Netzwerkbildung. Entsprechend war auch die 
Vaskularisierung und Inkorporation der Matrices verzögert. Dieses Ergebnis zeigt, dass 
MWD zur Behandlung größerer Wunden eingesetzt werden sollte, während ad-MVF-
besiedelte FWM eher in kleinen, irregulär geformten Wunden Anwendung finden könnte.  
 
In einem dritten experimentellen Teil wurde die Hypothese geprüft, ob eine zu geringe 
Dichte von ad-MVF bewirkt, dass eine ausreichende Vaskularisierung implantierter Matrices 
nicht mehr erfolgen kann. Hierzu wurden MWD mit 3 verschiedenen Dichten von ad-MVF 
besiedelt. Es konnte gezeigt werden, dass eine Mindestdichte von ~ 80,000 ad-MVF/cm2 
MWD notwendig ist, um eine ausreichende Vaskularisierung und Inkorporation der Matrices 
zu erreichen. Dies ist im Speziellen für klinische Anwendungen wichtig, bei denen am 
Patienten große Defekte gedeckt werden müssen und/oder ein eingeschränktes Volumen an 
Fettgewebe für die Isolierung von ad-MVF vorhanden ist.  
 
Neben dem Besiedeln von Matrices mit ad-MVF beschreibt der Einsatz der SVF aus 
Fettgewebe eine klinisch bereits angewandte Methode der Prävaskularisierung. In einem 
vierten experimentellen Teil wurde die Hypothese geprüft, ob eine Prävaskularisierung mit 
ad-MVF dem konventionellen SVF-basierten Ansatz überlegen ist. Obwohl ad-MVF- und 
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SVF-Isolate vergleichbare Anteile an Endothelzellen, perivaskulären Zellen, Adipozyten und 
Stammzellen aufwiesen, war die Viabilität von frisch isolierten ad-MVF höher. Weiterhin 
konnte gezeigt werden, dass SVF-besiedelte Matrices eine schlechtere Vaskularisierung 
aufweisen. Diese Ergebnisse zeigen, dass auf Grund ihres hohen 
Vaskularisierungspotentials ad-MVF gegenüber SVF-Einzelzellen für zukünftige Tissue 
Engineering-Ansätze deutlich besser geeignet sein könnten. 
 
In einem fünften experimentellen Teil wurde die Hypothese geprüft, ob die anti-angiogene 
Wirkung von niedermolekularen Heparinen (LMWH), wie Enoxaparin (enox), die 
Netzwerkbildung von ad-MVF verlangsamt. Weiterhin wurde hypothetisiert, dass die anti-
koagulativen Eigenschaften von enox zu vermehrten Einblutungen während der 
Netzwerkausbildung innerhalb ad-MVF-besiedelter Matrices führen. Hierzu wurden ad-MVF 
von GFP+ C57BL/6 Mäusen isoliert, welche mit enox oder Vehikel behandelt wurden. 
Anschließend wurde MWD mit diesen ad-MVF besiedelt und passgenau in Vollhautdefekte 
innerhalb des Rückenhautkammermodells implantiert. Intravitalmikroskopische, 
histologische, und immunhistochemische Analysen konnten zeigen, dass enox weder die 
Netzwerkbildung von ad-MVF verschlechtert, noch Einblutungen innerhalb der Matrices 
begünstigt. Diese Ergebnisse belegen, dass eine Besiedelung von MWD mit ad-MVF als 
Prävaskularisierungseinheiten bei gleichzeitig angewandter Thromboseprophylaxe 
problemlos möglich ist. 




As the largest organ of the human body skin does not only represent an important barrier for 
external threats, such as toxins and microorganisms, but also regulates the body 
temperature and maintenance of fluid homeostasis [ZHONG et al., 2010; SCHURR et al., 2012]. 
The vast variety of the skin´s functions is based on the complex composition of the two main 
structural compartments, dermis and epidermis, as well as their ability to interact with each 
other and to form a highly specialized matrix structure [NORMAN, 1998; BARONI et al., 2012].  
 
The epidermis, which is the outermost layer of the skin, is separated from the dermis through 
a basement membrane and consists of five different layers: stratum basale (basal layer), 
stratum spinosum (spinous layer), stratum granulosum (granular layer), stratum lucidum 
(clear layer), and stratum corneum (horny layer) [JOHNSTONE and FARLEY, 2005]. Stem cells, 
acting as regenerative elements, reside within the basal layer and are strongly attached to 
the underlying basement membrane in order to ensure the lifelong maintenance of the 
epidermis by their inexhaustible capacity to self-renew and to differentiate into all cell 
lineages [JENSEN et al., 1999; CANGKRAMA et al., 2013]. While cellular division exclusively 
takes place within this innermost layer of the epidermis, cells subsequently make their way 
through all other layers while progressively maturing and finally reaching the outermost 
stratum corneum [ZOUBOULIS et al., 2008]. Although the epidermis provides a stable 
environmental barrier for the first and initial protection of the organism against external 
threats, it is considered a rather thin cellular layer that highly depends on nutrient and 
biomechanical support from the underlying dermis [DALY, 1982].  
 
The dermis mainly consists of collagen (type I + III) and elastin fibers, which are both 
responsible for the skin´s overall elasticity and tensile strength [HUSSAIN et al., 2013]. 
Interestingly, biomechanical and compositional properties of the skin not only vary between 
anatomical regions, but are also age-related and, hence, change over time [GUNIN et al., 
2014]. A loss of the skin´s fundamental functions can be caused by various conditions, such 
as genetic disorders, chronic wounds, surgical interventions, or thermal trauma. Particularly 
the latter one can lead to skin defects of different severity levels classified by their wound 
depth and extent of tissue loss [EVERS et al., 2010; SHEVCHENKO et al., 2010]. Full-thickness 
skin defects, which are characterized by the complete destruction of both epidermis and 
dermis as well as the loss of all related and aforementioned regenerative elements, can 
particularly be caused by severe burns [PAPINI, 2004; SUPP and BOYCE, 2005; BELLAS et al., 
2012]. Accordingly, the rapid re-establishment of damaged skin is inevitable in order to 
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maintain its fundamental protective functions. Although small full-thickness skin defects are 
able to heal through re-epithelialization from the edges, wounds exceeding 1 cm in diameter 
require special treatment after the excision of the damaged tissue [PAPINI, 2004].  
 
In clinical practice, the gold standard for the treatment of full-thickness skin defects is split-
thickness skin grafting (STSG) [KIRSNER et al., 1997; RUSZCZAK, 2003; VAN DER VEEN et al., 
2010; MERUANE et al., 2012]. In this autologous approach, both epidermis and superficial 
parts of the dermis are harvested from a healthy skin donor site of the patient and 
subsequently transferred to the debrided wound bed [SHEVCHENKO et al., 2010]. After 
transplantation, capillaries of the skin graft connect to the vasculature of the underlying host 
tissue and, thus, allow the supply of nutrients ensuring graft tissue survival [SCHULTZ et al., 
2003; SHEVCHENKO et al., 2010]. However, several difficulties are associated with STSG. 
Besides the common problem of scarring [NGUYEN et al., 2010; VAN DER VEEN et al., 2010], 
the lack of suitable donor sites is a crucial issue when burn wounds exceed 50 - 60 % of the 
total body surface area [MACNEIL, 2007; REID et al., 2007; BÖTTCHER-HABERZETH et al., 
2010]. Furthermore, particularly wound beds with no adequate vascularization are unable to 
sufficiently re-connect with the implanted skin graft, resulting in a lack of oxygen and nutrient 
support.  
 
To counteract these problems, various bioengineered acellular off-the-shelf matrices, such 
as Integra®, Matriderm®, Glyaderm®, Biobrane®, or Alloderm®, have been introduced over the 
past decades [SUPP and BOYCE, 2005; ALRUBAIY and AL-RUBAIY, 2009; ZHONG et al., 2010; 
GRAHAM et al., 2013; SHAHROKHI et al., 2014; DEBELS et al., 2015]. When positioned within 
full-thickness skin defects, these matrices provide an immediate protection against 
dehydration and microorganisms and are progressively incorporated into the wound bed over 
time [DEBELS et al., 2015].  
 
Out of the aforementioned skin matrices, particularly Integra® Matrix Wound Dressing (MWD; 
Integra Life Sciences, Ratingen, Germany) is frequently used in clinical applications since 
many years [HUNT et al., 2000; JENG et al., 2007; KHAN et al., 2010; MERUANE et al., 2012; 
THINDA et al., 2012; GRAHAM et al., 2013; HULSEN et al., 2014; SINGER et al., 2015]. MWD 
consists of cross-linked bovine type I collagen and shark cartilage glycosaminoglycan that 
form a 1.3 mm thick porous structure with an average pore size of 30 - 120 µm [MERUANE et 
al., 2012; REIFFEL et al., 2012; CHOI et al., 2013]. In clinical routine, MWD, which is covered 
with a silicone pseudo-epidermis, is initially implanted into the debrided wound bed. Only 
after a sufficient vascularization of the matrix, the silicone layer is removed and the matrix 
can be covered with a skin graft of the patient [FRUEH et al., 2016]. However, an adequate 
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vessel ingrowth into the matrix may still require up to 3 weeks. Since wound infection is a 
threat throughout this time, a rather slow vascularization represents a major problem of this 
two-step-procedure and requires further optimization strategies [SHEVCHENKO et al., 2010; 
VAN DER VEEN et al., 2010; DEBELS et al., 2015].  
 
Over the past decades, various tissue engineering approaches have been developed to 
improve matrix vascularization. A common strategy is to stimulate the ingrowth of new blood 
vessels from the surrounding host tissue into implanted matrices via the process of 
angiogenesis, i.e. the development of new blood vessels from pre-existing ones [AUGER et 
al., 2013; BLANCO and GERHARDT, 2013]. To initiate this process, the host microvasculature 
needs to be activated by angiogenic growth factors, such as vascular endothelial growth 
factor (VEGF) or basic fibroblast growth factor (bFGF) [LASCHKE and MENGER, 2012]. One 
source of such growth factors may be the host tissue itself, which releases them due to 
tissue injury or as a consequence of an inflammatory response [LASCHKE et al., 2009]. The 
availability of such growth factors is not exclusively limited to their physiological niches. In 
fact, VEGF, bFGF, platelet-derived growth factor (PDGF), or angiogenin, are growth factors 
which are directly incorporated into matrices by coating technologies to improve their in vivo 
vascularization [LASCHKE and MENGER, 2012]. However, the survival of cells within matrices 
highly depends on their access to nutrients and oxygen. Since the transport of oxygen is 
limited to a diffusion distance of 150 - 200 µm, matrices that exceed a thickness of 400 µm in 
any dimension require rapid vascularization to ensure cell survival and oxygen influx as well 
as efflux of carbon dioxide and other cellular waste [AUGER et al., 2013]. Hence, although the 
coating with growth factors has been shown to enhance vascularization of seeded matrices 
[BAFFOUR et al., 1992], massive cell death still represents a major problem due to the long 
time needed for newly forming blood vessels to reach particularly core areas [PETITE et al., 
2000]. 
 
To overcome this problem, several prevascularization strategies have been developed over 
the last decades. They focus on the generation of a preformed microvasculature within 
bioengineered matrices prior to their implantation [LASCHKE and MENGER, 2016]. One 
frequently used approach is the seeding of matrices with vessel-forming cells, such as 
endothelial progenitor cells (EPCs). These cells can be assigned into early and late EPCs, 
depending on the time of their appearance during in vitro cultivation [HUR et al., 2004; 
DUTTENHOEFER et al., 2013; SASAGAWA et al., 2016]. Whereas early EPCs contribute to 
vessel formation by the secretion of angiogenic growth factors, late EPCs differentiate into 
endothelial cells and form capillary-like tubes [HUR et al., 2004; LASCHKE and MENGER, 2016]. 
Besides the seeding of matrices with EPCs, various other cell types, such as mesenchymal 
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stem cells [FORMIGLI et al., 2015; PILL et al., 2015], keratinocytes [GRIFFITH et al., 2005; 
AUGER et al., 2013], glandular-derived stem cells [EGAÑA et al., 2009], adipose-derived stem 
cells [MERUANE et al., 2012], dermal fibroblasts [AUGER et al., 2013], and induced pluripotent 
stem cell-derived endothelial cells [CLAYTON et al., 2015] have also been suggested to be 
suitable for the prevascularization of matrices. However, all cell-based prevascularization 
strategies are typically associated with complex and time-consuming cell isolation and 
cultivation procedures [VAN DER VEEN et al., 2010; LASCHKE and MENGER, 2016]. To address 
these problems, the seeding of matrices with adipose tissue-derived microvascular 
fragments (ad-MVF) has recently emerged as a novel and highly promising 
prevascularization concept. 
 
First described in 1975, ad-MVF from rats and mice have initially been used for the isolation 
of capillary endothelium in microcirculation and angiogenesis research as well as for 
functional sprouting assays [WAGNER et al., 1975; WAGNER and MATTHEWS, 1977; VARTANIAN 
et al., 2006]. Ad-MVF represent a randomized mixture of biologically intact arteriolar, 
capillary, and venular vessel segments that can easily be isolated in large amounts from 
adipose tissue by means of mechanical and enzymatic digestion [LASCHKE and MENGER, 
2015; FRUEH et al., 2017]. During the past years, ad-MVF have been increasingly used in 
experimental models for the analysis of tissue vascularization, angiogenesis, inosculation, 
and network remodeling [LASCHKE and MENGER, 2012; MCDANIEL et al., 2014; FRUEH et al., 
2017]. When compared to the aforementioned single cell seeding approaches, ad-MVF offer 
two main advantages. First, they can easily be isolated from adipose tissue within a relatively 
short isolation time of only ~ 10 minutes. Second, their intact vessel morphology, consisting 
of a central lumen, endothelium, and stabilizing mural cells, enables them to form 
interconnections with each other and the surrounding host tissue. This, in turn, leads to a 
rapid development of stable and blood-perfused networks within implanted matrices 
[LASCHKE and MENGER, 2015]. Furthermore, the length of isolated ad-MVF ranges between 
40 - 180 µm [PILIA et al., 2014], allowing them to rapidly bridge wide distances within seeded 
matrices. Moreover, ad-MVF not only release pro-angiogenic growth factors, but also 
represent a rich source of stem cells and EPCs [MCDANIEL et al., 2014; LASCHKE and 
MENGER, 2016]. MCDANIEL et al. [2014] reported that stem cells within isolated ad-MVF 
reside within their physiological niche and, hence, exhibit an elevated proliferation rate as 
well as a higher differentiation and vessel-forming capacity when compared to adipose 
tissue-derived single stem cells. So far, several experimental studies have shown that ad-
MVF accelerate matrix vascularization of random-pattern flaps [NAKANO et al., 1998], 
superficial myocardium [NAKANO et al., 1999], epicardial patches [SHEPHERD et al., 2007], 
volumetric muscle defects [PILIA et al., 2014], pancreatic encapsulating devices [HISCOX et 
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al., 2008], and matrices for tissue engineering [LASCHKE et al., 2012]. Besides these 
promising findings, it may be assumed that adipose tissue needed for the isolation of ad-
MVF in patients could easily be harvested by liposuction during surgery. Subsequently, the 
isolated ad-MVF may be used as vascularization units in an intra-operative one-step 
procedure. Accordingly, the aim of the present doctoral thesis was to test several 
hypotheses, which are of crucial importance for a transfer of this novel approach into clinical 
practice. 
 
For all in vitro and in vivo parts of this thesis, green fluorescent protein (GFP)+ C57BL/6 mice 
were used as donor animals for the harvesting of adipose tissue and the subsequent 
isolation of ad-MVF. The tissue of these animals appears green under blue light excitation 
[OKABE et al., 1997], enabling an easy identification of ad-MVF after their transplantation into 
GFP- C57BL/6 recipient mice. Non-seeded and ad-MVF- or stromal vascular fraction (SVF)-
seeded matrices were implanted into full-thickness skin defects within mouse dorsal skinfold 
chambers of GFP- C57BL/6 recipient mice to analyze their vascularization, incorporation, 
oxygenation, and epithelialization by means of intravital fluorescence microscopy, 
photoacoustic imaging, histology, and immunohistochemistry over an observation period of 
14 days. 
 
Due to an increasing life expectancy, elderly people may be the main target population for 
future clinical approaches that could benefit from ad-MVF as prevascularization units 
[LASCHKE et al., 2014]. However, previous studies have shown that both network formation 
and vascular remodeling are markedly affected in implanted matrices seeded with ad-MVF 
isolated from aged donors [LASCHKE et al., 2014]. Based on these observations, the 
hypothesis of a first set of experiments was that older mice also exhibit reduced amounts 
of adipose tissue as well as lower numbers of ad-MVF when compared to younger animals. 
For this purpose, epididymal adipose tissue was removed from donor animals within the age 
range of 7 - 12 months for the isolation of ad-MVF. Subsequently, the average volume of fat 
tissue as well as the number of isolated ad-MVF was determined. Furthermore, the average 
length, cellular composition, viability, and overall length distribution of individual ad-MVF 
were assessed by means of light microscopy. 
 
Besides MWD, Integra Life Sciences has developed a commercially available Flowable 
Wound Matrix (FWM) of identical composition for the treatment of complex and difficult-to-
access wound sites with irregular geometries [TRUONG et al., 2005; GREENWOOD et al., 2009; 
HIRCHE et al., 2016]. Whereas MWD is a ready-to-use sheet matrix, FWM is delivered as 
granulate which needs to be hydrated with sterile saline to achieve the injectable matrix of 
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gel-like consistency. Although MWD and FWM exhibit an identical material composition, 
variations in sample preparation and application may lead to crucial differences in their 
architectural properties. According to other studies, this may induce differences in the host 
tissue response after implantation and, hence, crucially determine the healing process 
[DRUECKE et al., 2004]. Previous studies have also shown that the pore size of biologically 
engineered matrices tremendously regulates their vascularization once implanted. In detail, 
matrices with pore sizes smaller than 200 µm favor the formation of vascular networks with 
small vessels at high densities, whereas networks with larger blood vessels and lower 
densities preferentially grow deeper into matrices with a pore size larger than 200 µm [CHOI 
et al., 2013]. It is also known that both fiber length and diameter represent crucial 
determinants for the incorporation process of implanted matrices. Penetrating cells are 
responsible for an adequate and homogeneous tissue growth inside the matrices and can 
bridge pores through the fibers [MORONI et al., 2006]. Therefore, in a second set of 
experiments it was hypothesized that the differences in MWD and FWM sample preparation 
lead to variations in pore size, fiber thickness, and fiber length. To test this, non-seeded 
MWD and FWM were prepared according to the manufacturer´s instructions and 
characterized by means of scanning electron microscopy and histology in vitro. Additionally, 
both matrices were implanted into full-thickness defects of C57BL/6 recipient mice to analyze 
their in vivo biocompatibility, vascularization, epithelialization, and tissue incorporation 
throughout an observation period of 14 days.  
Since previous studies have demonstrated that ad-MVF are rather large and, hence, mainly 
trapped in the superficial layers of seeded MWD [FRUEH et al., 2017], within this second 
experimental section it was further hypothesized that a more homogeneous seeding of ad-
MVF within FWM can be achieved and, hence, leads to improved matrix vascularization and 
incorporation. To test this, MWD and FWM were seeded with identical numbers of ad-MVF to 
assess their distribution and inter-fragment distance, i.e. the average distance of individual 
ad-MVF to each other. In addition, both ad-MVF-seeded matrices were implanted into full-
thickness skin defects within mouse dorsal skinfold chambers of GFP- C57BL/6 recipient 
mice to analyze their vascularization, epithelialization, and tissue incorporation.  
 
As described above, ad-MVF are able to interconnect with each other and the surrounding 
host tissue to form intact microvascular networks [FRUEH et al., 2017]. FRUEH et al. [2017] 
also reported that seeded ad-MVF mostly remain at the superficial layers of MWD. This, in 
turn, leads to a high density of ad-MVF within these superficial areas. Since the growth rate 
of angiogenic sprouts is reported to be ~ 5 µm/h [UTZINGER et al., 2015], the resulting 
relatively short distance between individual ad-MVF crucially determines the kinetics of the 
network formation process, leading to a rapid interconnection and onset of blood perfusion 
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within ad-MVF-seeded MWD. Accordingly, the hypothesis in a third set of experiments was 
that the seeding density of ad-MVF is a crucial determinant for the adequate vascularization 
and incorporation of matrices. To test this hypothesis, MWD was seeded with three different 
densities of ad-MVF and implanted into full-thickness skin defects within dorsal skinfold 
chambers of GFP- C57BL/6 recipient mice to analyze their in vivo vascularization and 
incorporation. 
 
Besides the novel ad-MVF-based approach, another common prevascularization strategy is 
the seeding of vessel-forming cells, such as endothelial cells or stem cells, onto matrices 
[STOSICH et al., 2007; SEEBACH et al., 2012]. However, blood vessels do not only exist of one 
specific cell type but exhibit a complex composition with an inner endothelial lining and 
surrounding vessel wall-stabilizing cell layers. Taking this into account, the SVF of adipose 
tissue is frequently used to induce the formation of microvascular networks [CERINO et al., 
2017; LOCKHART et al., 2017]. The SVF results from the enzymatic digestion of fat tissue and 
is a mixture of endothelial cells, pericytes, smooth muscle cells, and stem cells [BOURIN et 
al., 2013; HASSAN et al., 2014; MAIJUB et al., 2015; CERINO et al., 2017; LOCKHART et al., 
2017]. Of interest, the SVF is already evaluated in clinical trials for the regeneration of bone 
fractures or the treatment of idiopathic pulmonary fibrosis [TZOUVELEKIS et al., 2013; 
CHARLES-DE-SÁ et al., 2015; RIGOTTI et al., 2016; SAXER et al., 2016]. However, whereas ad-
MVF form new microvascular networks via direct interconnection, SVF single cells form a 
microvasculature de novo by reassembling into new blood vessels, which may take a much 
longer time. Accordingly, the hypothesis of a fourth set of experiments was that the ad-
MVF-based prevascularization of MWD is superior to the prevascularization with the SVF. To 
test this hypothesis, both ad-MVF and SVF single cells were isolated from adipose tissue of 
GFP+ C57BL/6 donor mice according to standard protocols. Subsequently, comparable 
amounts of the isolates were seeded onto MWD and implanted into full-thickness skin 
defects within dorsal skinfold chambers of GFP- C57BL/6 mice to analyze their 
vascularization and incorporation in vivo. 
 
In a fifth set of experiments it was hypothesized that the anti-angiogenic properties of low 
molecular weight heparins (LMWH), such as enoxaparin (enox), prevent the interconnection 
of seeded ad-MVF to microvascular networks. Enox is a frequently used drug for the daily 
thromboprophylactic treatment of hospitalized patients [LEIZOROVICZ et al., 1992; JØRGENSEN 
et al., 1993; BERGQVIST et al., 1996; MCLEOD et al., 2001; BERGQVIST et al., 2002; LASSEN et 
al., 2002; LEE et al., 2003; KAKKAR et al., 2008]. Of interest, studies have shown that the 
interaction of enox with tissue factor pathway inhibitor, tissue factor VIIa, and VEGF leads to 
a suppression of angiogenesis [DEBERGH et al., 2010; DOGAN et al., 2011]. Angiogenic sprout 
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formation, in turn, represents a crucial step in the reassembly of individual ad-MVF to newly 
developing microvascular networks as well as their interconnection with blood vessels of the 
surrounding host tissue [HOYING et al., 1996]. Besides its anti-angiogenic effect, enox also 
exhibits strong anti-coagulative properties, which can cause side effects, such as bleeding, 
during surgical interventions [RABAH et al., 1999; GERLACH et al., 2000; PETERSEN et al., 
2004]. Accordingly, it was further hypothesized that enox-treatment increases the bleeding 
risk during network formation within ad-MVF-seeded MWD. Enox inhibits one major player of 
the coagulation cascade, factor Xa [SPRONK et al., 2014]. This ultimately prevents the 
conversion of prothrombin to thrombin, which has an essential role in the clotting process by 
converting soluble fibrinogen to fibrin [ESMON, 2014]. This factor Xa inhibition has been 
reported to be directly associated with acute bleeding [DOCKAL et al., 2014; CONNOLLY et al., 
2016]. To test the two hypotheses of the fifth experimental section, ad-MVF were first 
isolated from epididymal fat pads of enox- and vehicle-treated GFP+ C57BL/6 donor mice. 
Subsequently, the isolated ad-MVF were seeded onto MWD and implanted into full-thickness 
skin defects within dorsal skinfold chambers of enox- and vehicle-treated GFP- C57BL/6 
recipient mice to analyze their vascularization, hemorrhage formation, and incorporation by 
means of intravital fluorescence microscopy, stereomicroscopy, histology, and 
immunohistochemistry over an observation period of 14 days.  
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4. Aim of the study 
 
The aim of the present doctoral thesis was to test several hypotheses, which are of crucial 
importance for transferring the novel approach of ad-MVF-based matrix prevascularization 
into clinical practice.  
In a first set of experiments it was hypothesized that older mice exhibit reduced amounts of 
adipose tissue as well as lower numbers of ad-MVF when compared to younger animals. 
The following questions were clarified: 
 Do older mice contain less adipose tissue when compared to younger ones? 
 Do older mice contain less numbers of ad-MVF in their adipose tissue when 
compared to younger ones? 
 Does the cellular composition and/or length distribution of ad-MVF, isolated from 
older donor animals, vary from that of ad-MVF isolated from younger animals? 
 
In a second set of experiments it was hypothesized that the differences in sample 
preparation between MWD and FWM lead to variations in pore size, fiber thickness, and fiber 
length. It was further hypothesized that a more homogeneous seeding of ad-MVF within 
FWM can be achieved and that this leads to improved matrix vascularization and 
incorporation. The following questions were clarified: 
 Do the varying sample preparations of MWD and FWM lead to different pore sizes, 
fiber length, and fiber thicknesses? 
 Can a more homogeneous distribution of ad-MVF within FWM be achieved when 
compared to MWD? 
 Does a more homogeneous distribution of ad-MVF within FWM lead to an improved 
vascularization and incorporation in vivo? 
 
In a third set of experiments it was hypothesized that the seeding density of ad-MVF is a 
crucial determinant for the adequate vascularization and incorporation of matrices. The 
following questions were clarified: 
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 Does a low density of ad-MVF lead to an insufficient vascularization and incorporation 
of seeded MWD? 
 Does a low density of ad-MVF lead to a reduced oxygenation of seeded MWD? 
 
In a fourth set of experiments it was hypothesized that the ad-MVF-based 
prevascularization of MWD is superior to the prevascularization with the SVF. The following 
questions were clarified: 
 Do isolated ad-MVF exhibit a higher viability when compared to SVF single cells? 
 Does an ad-MVF-based prevascularization lead to an improved vascularization and 
incorporation of seeded MWD when compared to a prevascularization with the SVF? 
 
In a fifth set of experiments it was hypothesized that the anti-angiogenic properties of enox 
prevent the interconnection of seeded ad-MVF to microvascular networks within seeded 
MWD. It was further hypothesized that the anti-coagulative properties of enox increase the 
bleeding risk during network formation within ad-MVF-seeded MWD. The following questions 
were clarified: 
 Do the anti-angiogenic properties of enox lead to reduced network formation within 
ad-MVF-seeded MWD? 
 Do the anti-coagulative properties of enox lead to increased hemorrhage formation 
within ad-MVF-seeded MWD? 
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5. Materials and methods 
 
5.1. Experimental animals 
All experiments of the present doctoral thesis were approved by the local government animal 
protection committee (permit numbers: 08/2015, 33/2016, 29/2017) and conducted in 
accordance with the European legislation on the protection of animals (Directive 2010/63/EU) 
as well as the NIH guidelines on the care and use of laboratory animals (NIH publication # 85 
- 23 Rev. 1985). Dorsal skinfold chambers were implanted in GFP- C57BL/6 recipient mice 
(Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany) 
with an age of 4 - 6 months and a body weight of 24 - 30 g. Epididymal fat pads were 
harvested from male GFP+ (C57BL/6-Tg(CAG-EGFP)1Osb/J donor mice (The Jackson 
Laboratory, Bar Harbor, ME, USA) with an age of 7 - 12 months and a body weight of > 30 g 
to guarantee large amounts of epididymal fat tissue containing a sufficient amount of ad-MVF 
or SVF single cells for the seeding and in vivo implantation of MWD and FWM or 
corresponding in vitro experiments. This transgenic mouse line is transfected with enhanced 
GFP cDNA under the control of a chicken β-actin promoter and cytomegalovirus enhancer 
[OKABE et al., 1997]. Accordingly, all tissues of these mice, except red blood cells or hair, 
appear green under blue light excitation, making it easy to detect GFP+ ad-MVF or SVF 
single cells in GFP- recipient mice [OKABE et al., 1997]. 
 
5.2. Experimental model 
5.2.1. MWD and FWM sample preparation 
For the in vitro and in vivo analyses in all experimental sections, MWD samples were cut out 
of a 1.3 mm thick dermal regeneration template single layer without silicone sheet (Figures 
1A and B; Integra Life Sciences) with a 4 mm biopsy punch (kai medical, kaiEurope GmbH, 
Solingen, Germany). For the second experimental section, samples of FWM were 
additionally generated according to the manufacturer’s instructions (Integra Life Sciences) by 
hydrating 1.25 mg of granulated collagen-glycosaminoglycan with 15 µL sterile 0.9 % NaCl. 
In detail, the dry collagen-glycosaminoglycan granulate was carefully placed in a petri dish 
under sterile conditions and a 20 mL pipette was used to evenly distribute the fluid over the 
granulate. Subsequently, fine tweezers were used to carefully admix both components to a 
homogeneous matrix with gel-like consistency (Figures 1C and D). Finally, the matrices were 
used for in vitro characterizations or implanted into full-thickness skin defects within dorsal 
skinfold chambers of GFP- C57BL/6 recipient mice for in vivo analyses.  
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Figure 1. A: Cutting MWD samples out of a dermal regeneration template single layer with a 4 mm biopsy punch. 
Scale bar = 10 mm. B: MWD on the tip of a micro forceps after preparation. Scale bar = 2 mm. C: Careful 
homogenization of dry FWM granulate and 0.9 % NaCl inside a sterile petri dish. Scale bar = 2 mm. D: Gel-like 
FWM on the tip of a micro forceps after sample preparation. Scale bar = 2 mm.  
 
5.2.2. Scanning electron microscopy 
Scanning electron microscopy was used to observe the morphology of MWD and FWM 
samples. First, samples were fixed using 2 vol. % glutardialdehyde (Science Services GmbH, 
Munich, Germany) in 0.1 M sodiumcacodylate buffer at pH 7.4 (Carl Roth GmbH & Co KG, 
Karlsruhe, Germany) for 10 minutes at room temperature under slow movement. 
Subsequently, the samples were stored at 4 °C for 24 hours. Thereafter, the samples were 
washed with 0.1 M sodiumcacodylate buffer and incubated in osmium tetroxide (1 vol. % in 
0.2 M sodiumcacodylate buffer) for 1 hour under slow movement and the absence of light. All 
samples were then washed four times for 10 minutes in distilled water (dH2O) before being 
dehydrated by the incubation in an ascending ethanol series (70 vol. %, 80 vol. %, 90 vol. %, 
96 vol. %, and 100 vol. %) under slow movement. By washing the samples in a mixture 
(50:50) of 100 vol. % ethanol and hexamethyldisilazane (Carl Roth GmbH Co KG), followed 
by washing in pure hexamethyldisilazane, the dehydration was completed. The samples 
were subsequently covered with hexamethyldisilazane, which evaporated over night. The 
next day, samples were transferred into conductive carbon adhesive tabs (Plano GmbH, 
Wetzlar, Germany) and sputtered to make them conductive as a prerequisite for the analysis. 
The sputtering was performed 3 times for each 60 seconds with gold (SCD 005, Balzers 
Union, Balzers, Liechtenstein). Then, additional sputtering was performed with carbon (SCD 
030, Balzers Union). Lastly, the samples were analyzed be means of a FEI XL 30 ESEM 
FEG scanning electron microscope (FEI, Hillsboro, OR, USA) under high vacuum conditions 
at an acceleration voltage of 5 kV in secondary electrons mode. 
 
5.2.3. Isolation of ad-MVF 
For the isolation of ad-MVF, GFP+ C57BL/6 donor mice were anesthetized by an 
intraperitoneal injection of xylazine (25 mg/kg body weight; Rompun®; Bayer, Leverkusen, 
Germany) and ketamine (75 mg/kg body weight; Ursotamin®; Serumwerke Bernburg, 
Bernburg, Germany) [GREEN et al., 1981; SAHA et al., 2005]. Subsequently, the animals were 
transferred onto an operation table in supine position and placed under a stereomicroscope. 
Paws of the animals were immobilized by taping them to a surgical drape and the abdomen 
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was depilated with both a razor (AESCULAP ISIS Gt420, Tuttlingen, Germany) and 
depilatory cream (Asid®-med, ASID BONZ, Herrenberg, Germany) followed by disinfection 
(Octeniderm®, Schülke & Mayr AG, Norderstedt, Germany) (Figure 2A). Thereafter, a midline 
laparotomy was performed to gain access to the epididymal fat pads (Figure 2B). Finally, the 
fat pads were harvested and transferred into a petri dish containing 15 mL Dulbecco´s 
Modified Eagle Medium (DMEM) (PAN Biotech GmbH, Aidenbach, Germany) pre-heated to 
37 °C (Figure 2C). Lastly, the animals were sacrificed by cervical dislocation.  
 
 
Figure 2. A: Immobilized, depilated, and disinfected animal in supine position before midline laparotomy (broken 
line). Scale bar = 10 mm. B: Opened abdomen with laterally unfolded abdominal walls to access the epididymal 
fat pads (white broken lines). Arrows = epididymis. Asterisk = bladder. Scale bar = 10 mm. C: Harvested 
epididymal fat pads (arrows) in 15 mL DMEM. Scale bar = 17 mm.   
 
After their harvesting, the epididymal fat pads were washed thrice in phosphate-buffered 
saline (PBS) inside a laminar flow hood (Figure 3A). Subsequently, the fat tissue was 
transferred into a 14 mL polypropylene (PP) tube to assess its volume by means of the tube 
scale. Until a homogeneous suspension was achieved (Figure 3B), the fat tissue was minced 
mechanically with fine scissors. One volume of the minced tissue was then transferred into a 




Figure 3. A: Harvested epididymal fat pads (arrows) in PBS during the washing process. Scale bar = 22 mm. B: 
Mechanically minced fat pads inside a 14 mL PP tube. Scale bar = 22 mm. C: Stirred fat tissue during enzymatic 
digestion. Scale bar = 50 mm. D: Fat supernatant (double arrow) after gravity separation. Scale bar = 26 mm. E: 
Isolated ad-MVF (arrowheads) at the end of the isolation process. Scale bar = 60 µm.    
 
Subsequently, the tissue was digested for ~ 10 minutes under gentle stirring inside an 
incubator at 37 °C and 5 % CO2 (Figure 3C). A constant monitoring of 3 µL fractions of the 
digested tissue was conducted by light microscopy (Leica DFC450C, Leica, Wetzlar, 
*
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Germany) to determine the time when the ad-MVF were sufficiently separated from the fat 
tissue and the digestion had to be stopped by neutralizing the collagenase activity with two 
volumes of PBS (+ 20 % fetal calf serum (FCS)). The cell-vessel suspension was then 
transferred into a 14 mL PP tube and incubated for 5 minutes at 37 °C to separate the 
remaining fat by gravity (Figure 3D). To remove remaining fat clots, a 500 µm mesh was 
subsequently used to filter the suspension (pluriSelect Life Science, Leipzig, Germany). Ad-
MVF were then enriched to a pellet by centrifugation for 5 minutes at 600 x g. Finally, the 
supernatant was completely removed and the obtained pellet resuspended in the required 
final volume of PBS (+ 20 % FCS) for in vitro characterization or the seeding of MWD or 
FWM for in vivo analyses. A final microscopic observation confirmed the successful isolation 
of ad-MVF (Figure 3E). Noteworthy, the obtained pellet for matrix seeding not only contained 
purified ad-MVF but also single cells. Hence, the in the following sections called ad-MVF 
represented a cell-vessel suspension (Figure 4A).  
 
5.2.4. Isolation of SVF single cells 
To isolate SVF single cells, adipose tissue was harvested from the epididymal fat pads of 
GFP+ C57BL/6 mice and mechanically minced, as previously described in section 5.2.3. The 
tissue was then enzymatically digested with collagenase NB4G (0.5 U/mL) for 60 minutes 
under constant stirring inside an incubator at 37 °C and 5 % CO2.  
 
 
Figure 4. A: Cell-vessel suspension directly after the isolation of ad-MVF. Arrowheads = ad-MVF. Arrows = single 
cells. B: Single cells (arrows) representing the SVF at the end of the isolation process. Scale bars = 37 µm. 
 
The digestion was stopped by neutralizing the enzymatic activity with two volumes of PBS (+ 
20 % FCS) before the suspension was transferred into a 14 mL PP tube and incubated for 5 
minutes at 37 °C to separate the remaining fat by gravity. Once the supernatant was 
successfully removed, the suspension was filtered through a 40 µm mesh to remove all 
undigested fat clots and ad-MVF. Single cells were collected, transferred into a 14 mL PP 
tube, and centrifuged for 5 minutes at 600 x g. The supernatant was then removed until 1 mL 
was left. Within this volume, the single cells were resuspended, transferred into a 1.5 mL 
tube, and centrifuged again under identical conditions. Finally, the isolated single cells, 
representing the SVF (Figure 4B), were used for in vitro characterization or seeded onto 
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MWD for in vivo analyses. Noteworthy, ~ 4,000,000 single cells represented the SVF isolate 
from 1 mL epididymal adipose tissue, corresponding to ~ 40,000 ad-MVF resulting from the 
isolation of an equivalent fat tissue volume.   
 
5.2.5. Characterization of ad-MVF and SVF single cells 
GFP+ animals of the first experimental section were assigned to 6 age groups (7, 8, 9, 10, 11, 
and 12 months old) and the average harvested fat tissue volume per mouse was assessed. 
After ad-MVF isolations in each age group, 10 % of the final cell-vessel suspension were 
diluted 1:10 in PBS and 100 µL of this dilution transferred into a 96-well plate to assess the 
number of ad-MVF per mL as well as their average size and overall size distribution by 
means of microscopic counting and extrapolation. A Neubauer counting chamber was used 
to determine the total number of SVF single cells. 
 
5.2.5.1. Viability 
At the end of the isolation process, the final pellet of either ad-MVF or SVF single cells was 
resuspended in 1 mL PBS including 2 mg/mL bisbenzimide (Bb) and 1 mg/mL propidium 
iodide (PI) (Figures 5A-C). The suspension was incubated for 10 minutes at 37 °C and 5 % 
CO2. Then, a 20 µL fraction of each suspension was transferred into a petri dish and the 
viability of cells in ~ 50 randomly selected ad-MVF or ~ 1000 SVF single cells was assessed 
per isolate. For this purpose, Bb was used to stain all cell nuclei of ad-MVF and SVF single 
cells via binding to their DNA (Figure 5A). Since PI is a red fluorescent dye that only 
penetrates through damaged cell membranes, it was used as a marker for dead cells 
(Figures 5B and C) [DENGLER et al., 1995; SHI et al., 2007]. 
 
 
Figure 5. A: Bb staining of all ad-MVF cell nuclei. B: PI staining of damaged/dead cells. C: Merge of A and B, 
indicating which of the ad-MVF cells are damaged/dead. Arrows = damaged cellular fraction of ad-MVF. Scale 
bars = 60 µm. 
 
5.2.5.2. Cellular composition 
The cellular composition of ad-MVF or SVF single cells was analyzed by means of flow 
cytometry. For this purpose, the isolated ad-MVF cell-vessel suspension was further digested 
into single cells with Accutase® (BioLegend, Fell, Germany) for 30 minutes. The resulting ad-
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MVF single cells or SVF single cells were then analyzed for the expression of the endothelial 
cell marker CD31 and the perivascular cell marker α-smooth muscle actin (α-SMA) by using 
a monoclonal rat anti-mouse CD31-phycoerythrin (PE) antibody (BD Biosciences, 
Heidelberg, Germany) and a monoclonal rat anti-mouse α-SMA antibody (Thermo Fisher 
Scientific Inc., Waltham, MA, USA). Additionally, both cell populations were analyzed for the 
expression of the stromal/stem cell surface markers CD117, CD90, and CD29 by using a 
monoclonal rat anti-mouse CD117-fluorescein isothiocyanate (FITC) antibody (BD 
Biosciences) as well as a mouse anti-rat/mouse CD90-FITC antibody (BioLegend) and a 
monoclonal hamster anti-rat/mouse CD29-FITC antibody (BioLegend). Isotype identical rat 
IgG-PE or rat IgG-FITC (BD Biosciences), mouse IgG-FITC (BD Biosciences), and hamster 
IgG-FITC antibodies (BioLegend) served as controls. Finally, the cells were also analyzed for 
the expression of the adipocyte marker adipocyte-specific adhesion molecule (ASAM) by 
using a purified polyclonal sheep anti-mouse/human antibody (R&D Systems, Wiesbaden, 
Germany) followed by a secondary donkey anti-sheep IgG-Alexa488 antibody (Molecular 
Probes, Eugene, OR, USA). All flow cytometric analyses were performed by means of a 
FACScan (BD Biosciences). Data were assessed using the software package Cell-Quest Pro 
(BD Biosciences).  
 
5.2.6. Seeding of MWD and FWM 
For the second and fifth set of experiments, MWD samples were placed on a 500 µm cell 
strainer and 15 µL 0.9 % NaCl, containing ~ 15.000 ad-MVF (second set of experiments) or ~ 
10.000 ad-MVF (fifth set of experiments), were transferred onto the matrices with a 20 µL 
pipette (Eppendorf, Wesseling-Berzdorf, Germany) under the application of negative 
pressure to assure a sufficient seeding depth (Figures 6A-C).  
  
 
Figure 6. A: Ad-MVF cell-vessel suspension within a 20 µL pipette before seeding. B: Seeding of the ad-MVF 
cell-vessel suspension onto a MWD sample. Note that the ad-MVF mainly remain at the superficial part of the 
matrix. C: Deeper penetration of single cells into MWD, initiated by the application of negative pressure from 
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For the second set of experiments, FWM was prepared according to the manufacturer´s 
instructions by hydrating 1.25 mg of the granulated collagen-glycosaminoglycan with 15 µl of 
0.9 % NaCl, either containing ~ 15.000 ad-MVF or vehicle only. After the admixture process, 
the matrix presented a gel-like consistency and was used for in vitro characterization or in 
vivo analyses. 
 
For the third set of experiments, different densities of ad-MVF were seeded onto MWD and 
subsequently analyzed in vivo. Besides the previously used number of ~ 15.000 ad-MVF, 
which was defined as a high density (HD) and served as control group, lower numbers of ~ 
10.000 ad-MVF (medium density; MD) and ~ 5.000 ad-MVF (low density; LD) were 
additionally seeded in additional groups (Figure 7). 
 
 
Figure 7. MWD was seeded with different numbers of ad-MVF, including ~ 15.000 (high density; HD), which 
served as control group, as well as ~ 10.000 (medium density; MD) and 5.000 ad-MVF (low density; LD). 
 
For the fourth set of experiments, ~ 10.000 ad-MVF including ~ 200.000 single cells, 
resulting from a digestion of 250 µL adipose tissue, were enriched to a final pellet and 
subsequently resuspended in 10 µL 0.9 % NaCl for matrix seeding. All SVF single cells from 
250 µL adipose tissue, i.e. ~ 1,000,000 cells, were also resuspended in 10 µL 0.9 % NaCl for 
the SVF-seeding of MWD, corresponding to the equivalent overall number of cells per ad-
MVF-seeded matrix. Of note, to prevent the extraction of single cells from the seeded 
matrices, no negative pressure was applied during the seeding process in the fourth set of 
experiments.  
 
5.2.7. Implantation of the dorsal skinfold chamber 
To analyze implanted MWD or FWM in vivo, a modified mouse dorsal skinfold chamber 
model was used according to SORG et al. [2009]. First described in 1943, the dorsal skinfold 
chamber model can be used to study the microcirculation in living animals by means of 
intravital fluorescence microscopy [ALGIRE, 1943; PAPENFUSS et al., 1979; LEHR et al., 1993; 
LASCHKE et al., 2011]. For the implantation of the dorsal skinfold chamber (Irola 
Industriekomponenten GmbH & Co. KG, Schonach, Germany), which consists of two 
symmetrical titanium frames (Figure 8A), the mice were first anesthetized by intraperitoneal 
injection of ketamine and xylazine, as previously described.  
~ 15.000 ad-MVF ~ 10.000 ad-MVF ~ 5.000 ad-MVF
HD MD LD
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Figure 8. A: Dorsal skinfold chamber, consisting of two symmetrical titanium frames (a = holes for suturing the 
frame to the dorsal skinfold of the mouse, b = observation window, c = connecting screw, d = recess for weight 
reduction). Scale bar = 8 mm. B: Cranially and caudally affixed dorsal skinfold of a GFP 
-
 C57BL/6 mouse. Scale 
bar = 8 mm. C: Screws (arrows) through the skin of the mouse to connect the second titanium frame. Scale bar = 
5 mm. D: Connected second titanium frame including a snap ring for the hermetical closure of the chamber 
tissue. Scale bar = 9 mm.   
 
As soon as a deep anesthesia of the animals was confirmed by toe pinch, the fur was first 
roughly and then chemically removed from the animals´ back by means of a razor (Isis 
GT608, Aesculap GmbH, Suhl, Germany) and depilatory cream (asid-med crème, Asid Bonz 
GmbH, Herrenberg, Germany). To prevent cream-induced inflammatory irritations, the hair-
free back was cleaned with both warm water and medical disinfectant spray (Schülke & Mayr 
AG, Zürich, Switzerland). Thereafter, the skinfold of the mice was cranially and caudally 
affixed at midline by two silk sutures (Figure 8B). One titanium frame of the chamber was 
fixed to the back side of the skinfold on its superior edge before two openings were prepared 
at the base of the skinfold in order to pass through the connecting screws from the back side 
to the front side (Figure 8C). By means of these screws, the second frame was connected to 
the first one. Screw nuts and the subsequent hermetical closure of the chamber tissue with a 
cover glass and a snap ring finalized the preparation procedure (Figure 8D). To maintain the 
body temperature throughout the operation procedure, the animals were constantly 
positioned near a heat source. Furthermore, eyes were covered with Bepanthen® 
moisturizing cream (Bayer Vital GmbH, Leverkusen, Germany) to prevent their desiccation. 
To further avoid postoperative alterations of the local microcirculation due to anesthesia and 
surgery, the mice were allowed to recover for 48 hours after the chamber preparation. 
 
5.2.8. Preparation and filling of full-thickness skin defects 
Forty-eight hours after implantation of the dorsal skinfold chamber, a full-thickness skin 
defect was created in the center of the observation window. For this purpose, the 
anesthetized mice were fixed on a Plexiglas stage and the skinfold chamber was horizontally 
positioned under a stereomicroscope (Leica M651, Leica). A 4 mm biopsy punch was used 
to carefully mark the outlines of the 4 mm defect on the skin of the mice (Figure 9A). 
Subsequently, microsurgical instruments were used to create a roundly shaped full-thickness 
skin defect by removing the epidermis, the dermis, and the underlying muscle layers 
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Figure 9. A: Outlines (arrows) of the skin defect, gently marked by a 4 mm biopsy punch. Scale bar = 3 mm. B: 
Full-thickness skin defect (arrow). Scale bar = 4 mm. C: Filling of the full-thickness skin defect with non-seeded 
MWD (arrow). Scale bar = 6.6 mm. D: Skin defect, covered with a cover glass that is fixed with a snap ring 
(arrow). Scale bar = 5 mm. E: GFP 
-
 C57BL/6 recipient mouse showing normal behavior 48 hours after the 
creation of a full-thickness skin defect within the dorsal skinfold chamber. Scale bar = 9 mm. 
 
 
Figure 10. A-C: Epi-illumination stereomicroscopy of non-seeded MWD within the dorsal skinfold chamber of a 
GFP 
-
 C57BL/6 recipient mouse on day 0 (A), 6 (B), and 14 (C) after implantation. Closed lines = matrix border. 
Broken lines = non-epithelialized area. Scale bars = 1.4 mm. D-I: Trans-illumination stereomicroscopy of ad-MVF-
seeded MWD within the dorsal skinfold chamber of GFP 
-
 C57BL/6 recipient mice, displaying different 
manifestations of matrix-induced bleedings according to a semi-quantitative hemorrhagic score, i.e. 1: No 
bleeding (D), 2: 1-25 % (E), 3: 26-50 % (F), 4: 51-75 % (G), 5: 76-100 % (H), 6: Bleeding exceeding matrix 
surface (I). Scale bars = 1.3 mm. 
 
Directly after the creation of the full-thickness skin defect, non-seeded, ad-MVF-seeded, or 
SVF-seeded MWD or FWM were carefully placed into the wound bed (Figure 9C). After the 
matrices were inserted, the observation window of the chamber was closed by means of a 
removable cover glass and a snap ring (Figure 9D). Shortly after the implantation, the mice 
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5.2.9. Stereomicroscopy 
To analyze epithelialization (Figures 10A-C) and hemorrhage formation (Figures 10D-I) of 
the implanted matrices by means of planimetry, the anesthetized animals were fixed on a 
Plexiglas stage and the dorsal skinfold chamber was positioned under a stereomicroscope 
(Leica M651, Leica). The chamber tissue was then visualized in epi-illumination to detect 
epithelialized and non-epithelialized matrix areas. To allow a quantitative analysis by means 
of the computer-assisted system CapImage (Zeintl, Heidelberg, Germany), a DVD system 
was used to record all microscopic images. The epithelialized area (% of the total matrix 
area) was calculated by the equation: (Total matrix area - non-epithelialized matrix area) / 
(total matrix area) * 100. In addition, trans-illumination was used to evaluate the extent of 
hemorrhage formation (% of matrix surface area) by means of a semi-quantitative 
hemorrhagic score as follows: 1: No bleeding, 2: 1-25 %, 3: 26-50 %, 4: 51-75 %, 5: 76-100 
%, 6: Bleeding exceeding matrix surface (Figures 10D-I).  
 
5.2.10. Intravital fluorescence microscopy 
Intravital fluorescence microscopy was used to analyze the in vivo vascularization of 
implanted MWD or FWM over time. By means of this technique, specifically dynamic 
processes, such as angiogenesis, can be repetitively visualized and recorded for the 
quantitative assessment of microhemodynamic parameters. For contrast enhancement, 0.1 
mL of the plasma marker 5 % FITC-labeled dextran (150,000 Da; Sigma-Aldrich, 
Taufkirchen, Germany) were injected intravenously (i.v.) into the retrobulbar venous plexus 
of the anesthetized mice. Then, the observation window of the chamber was placed under an 
Axiotech microscope (Zeiss, Oberkochen, Germany). Images were recorded with a charge-
coupled device video camera (FK6990; Pieper, Schwerte, Germany) and stored on DVD for 
off-line analyses. The analyses were performed by the computer-assisted off-line analysis 
system CapImage (Zeintl). The vascularization of implanted, non-seeded and ad-MVF-
seeded MWD or FWM within the second, third, and fifth set of experiments was assessed in 
12 regions of interest (ROIs), 6 along the total vertical and horizontal axis of each matrix 
(Figure 11A). The vascularization of implanted, ad-MVF- or SVF-seeded MWD in 
experimental section 4 was separately assessed in 4 ROIs of each matrix´ center and border 
zones (Figure 11B). Each ROI that exhibited red blood cell (RBC)-perfused microvessels 
was defined as a perfused ROI (% of all counted ROIs). Furthermore, the functional 
microvessel density was measured as the total length of all RBC-perfused microvessels per 
ROI (cm/cm2). Additionally, the diameter (d, µm) and the centerline RBC velocity (v, µm/s) of 
40 randomly selected microvessels were assessed (Figures 12A and B). The latter 
parameter was measured using the line-shift method [DE VRIESE et al., 1995] (Figure 12D). 
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For this purpose, a measurement line is defined within the lumen of each blood vessel of 
interest and the blood flow is recorded in real-time for 10 seconds (Figure 12C).  
 
 
Figure 11. A, B: Overview of the dorsal skinfold chamber observation window showing defined ROIs for intravital 
fluorescence microscopic assessment of microhemodynamic parameters in experimental protocols 2, 3, and 5 (A) 
as well as 4 (B). Black frames in A = 12 ROIs along the vertical and horizontal axis of the matrix. Blue and white 
frames in B = border (blue) and center (white) zones of implanted matrices. Scale bars = 1.5 mm. 
 
 
Figure 12. A: ROI of implanted MWD on day 0 (day of implantation), showing no microvessels within the matrix. 
Asterisk = matrix. Dotted line = matrix border. Scale bar = 500 µm. B: ROI with fully perfused MWD on day 14 
after implantation into a full-thickness skin defect of a GFP 
-
 C57BL/6 recipient mouse. Dotted line = matrix 
border. Arrows = microvessels. Scale bar = 500 µm. C: Measurement of microvessel diameter (blue lines) and 
centerline RBC velocity (dotted red lines). Scale bar = 100 µm. D: Illustration of the line shift diagram for the 
measurement of centerline RBC velocity. Red lines = Resulting slope from the measurement of the blood flow.  
 
During this time, the grey value of every field of image is continuously created along the 
defined measurement line and stored on a memory unit. Accordingly, the computer 
generates a line-shift diagram based on all consecutive grey values. This diagram shows 
bright and dark lines that result from gaps inside the blood plasma or erythrocytes flowing 
along the measurement line (Figure 12D). Based on the slope of these lines, the final velocity 
is calculated. Additionally, vessel diameter and centerline RBC velocity were used to 
calculate the wall shear rate (y, s-1) of individual microvessels by means of the Newtonian 
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5.2.11. Ultrasound and photoacoustic imaging 
Ultrasound and photoacoustic imaging were used to measure the hemoglobin oxygen 
saturation (sO2) of non-seeded and ad-MVF-seeded MWD by means of a Vevo LAZR system 
(VisualSonics Inc., Toronto, ON, Canada) and a real-time microvisualization LZ550 linear-
array transducer (VisualSonics Inc.). This transducer worked with a center frequency of 40 
MHz. All samples were embedded in ultrasound gel (Aquasonic 100; Parker, Fairfield, NJ, 
USA) to prevent interference with ultrasound coupling. For in vitro analyses, freshly seeded, 
non-implanted MWD (Figures 13A and B) was first analyzed to assess the values of 
oxygenation within ad-MVF directly after their seeding onto the matrix. 
 
 
Figure 13. A-D: B-mode ultrasound (A, C) and photoacoustic imaging (B, D) of ad-MVF-seeded MWD directly 
after seeding (A,  B) as well as 14 days after implantation into full-thickness skin defects within dorsal skinfold 
chambers of GFP 
-
 C57BL/6 recipient mice (C, D). Broken lines = matrix border. Red areas = high oxygenation. 
Blue areas = low oxygenation. Black areas = No oxygenation. Scale bars = 600 µm.   
 
To further assess the oxygenation of implanted, ad-MVF-seeded matrices in vivo (Figures 
13C and D), chamber-equipped mice were first anesthetized with 1.5 % isofluorane in air and 
fixed in prone position on a heated stage. Both heart rate and breathing rate were constantly 
monitored while the body temperature was maintained at 37 °C (THM100; Indus Instruments, 
Houston, TX, USA). Noise signalling, which may originate from the titanium frames, was 
prevented by covering the skinfold chamber with a 3 mm soft polyvinyl chloride (PVC) mask 
(Sagustu International GmbH, Bruchmühlbach-Miesau, Germany). To achieve three-
dimensional high- resolution B-mode ultrasound images, the scanhead was driven by a linear 
motor, acquiring two-dimensional images at regular spatial intervals, parallelly and uniformly 
spaced at 150 µm intervals over the entire matrix. Photoacoustic images were taken to 
detect sO2 within the samples at 850 nm with a two-dimensional gain of 34 dB in vitro and 32 
dB in vivo [RICH and SESHADRI, 2015]. All values were calculated by means of the Vevo LAB 
software (FUJIFILM VisualSonics Inc.). 
 
5.2.12. Tail vein bleeding time 
In the fifth set of experiments, the tail vein bleeding time was measured in enox- and vehicle-
treated animals. For this purpose, a transverse incision over the lateral tail vein was made. 
The cut was performed where the diameter of the tail was ~ 2.5 mm. This was ~ 25 mm 
proximal from the tail tip (Figure 14A). The tail was immediately placed in 0.9 % NaCl, pre-
heated to ~ 37 °C, and the time from the incision to the cessation of bleeding was measured 
as tail vein bleeding time [BROZE et al., 2001] (Figures 14B-D).   
A B C D
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Figure 14. A: For the assessment of the tail vein bleeding time, the cut position was marked ~ 25 mm proximal 
from the tail tip. Scale bar = 6 mm. B: Tail placed inside 37 °C warm 0.9 % NaCl directly after incision. Leaking 
blood forming a downward moving thread (arrow). Scale bar = 20 mm. C: Cessation of bleeding, as defined as 
the time point when the blood flow exhibits gaps (arrow). Scale bar = 20 mm. D: Insert of C, showing the time 
point of cessation. Arrow = gap of broken blood thread, indicating the cessation of bleeding. Scale bar = 5 mm. 
 
5.3. Histology 
For histological analyses, all analyzed MWD specimens were fixed in formalin (Carl Roth 
GmbH & Co. KG, Karlsruhe, Germany). To prevent FWM samples of the second 
experimental section from dissolving in formalin, they were embedded in Tissue-tek® O.C.T. 
compound (A. Hartenstein GmbH, Würzburg, Germany) with following quick-freezing in liquid 
nitrogen at -196 °C. All samples were subsequently cut into 3 µm thick sections and 
processed for histological analyses. 
 
5.3.1. Matrix incorporation 
First, a hematoxylin and eosin (HE) staining was performed according to standard 
procedures (Figure 15).  
 
 
Figure 15. Representative HE staining of non-seeded MWD on day 14 after implantation into a full-thickness skin 
defect within a dorsal skinfold chamber of a GFP 
-
 C57BL/6 recipient mouse. Broken line = matrix border. 
Asterisks = border zones of the matrix. Arrows = panniculus carnosus muscle of the dorsal skinfold chamber 
preparation. Scale bar = 350 µm.  
 
To assess fiber length (Figure 16A), fiber thickness (Figure 16B), and pore size (Figure 16C) 
of non-implanted MWD and FWM in the second experimental section, 5 randomly selected 
ROIs per HE-stained section were analyzed by using a BX60 microscope (Olympus, 
Hamburg, Germany) and the imaging software cellSense Dimension 1.11 (Olympus).  
A B C D
*
*
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Figure 16. A-C: Representative HE staining of FWM for the in vitro measurement of fiber thickness (A; black line, 
arrows), fiber length (B; black lines), and interfiber distance (C; black lines). Scale bars = 40 µm. 
 
5.3.2. Collagen content 
The reddish appearance of Sirius red under polarized light [JUNQUEIRA et al., 1979; RADHIKA 
et al., 2016] was used to visualize mature collagen fibers in normal skin and within non-
seeded, ad-MVF-seeded, or SVF-seeded MWD and FWM (Figures 17A-C) in 4 ROIs of each 
sample using a BX60 microscope (Olympus) and the imaging software cellSense Dimension 
1.11 (Olympus). The total collagen ratio (%) was assessed by dividing the density of collagen 
fibers within the matrices with the density of collagen fibers of the normal skin.   
 
 
Figure 17. A-C: Polarized light microscopy of Sirius red-stained sections of normal skin (A) as well as ad-MVF-
seeded, vehicle-treated (B) and enox-treated (C) MWD 14 days after implantation into full-thickness skin defects 
within dorsal skinfold chambers of GFP 
-




To confirm the stereomicroscopic results of matrix epithelialization on day 14 after 
implantation, sections of the largest cross-sectional diameter of ad-MVF or SVF-seeded 
MWD or FWM were incubated with a rabbit polyclonal anti-cytokeratine antibody (1:100; 
Abcam, Cambridge, UK) as primary antibody followed by a biotinylated goat anti-rabbit IgG 
antibody (ready-to-use; Abcam) as secondary antibody. The biotinylated antibody was 
detected by peroxidase-labeled-streptavidin (1:50; Sigma-Aldrich) and 3-amino-9-
ethylcarbazole (Abcam) was used as chromogen. 
A B C
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Figure 18. Immunohistochemical detection of the cytokeratine
+
 epithelial layer (arrowhead) covering non-seeded 
MWD on day 14 after implantation into a full-thickness skin defect within a dorsal skinfold chamber of a GFP 
-
 
C57BL/6 recipient mouse. The double arrow indicates the epithelialized part of the matrix. Scale bar = 125 µm. 
 
To assess the cytokeratine+ epithelial layer (Figure 18), a BZ-8000 microscopic system 
(Keyence, Osaka, Japan) was used and the total matrix diameter was measured. 
Subsequently, the length of the epithelialized matrix surface was detected. Matrix 
epithelialization was then calculated as: length of cytokeratine+ epithelial layer / total diameter 
of matrix * 100. 
 
5.4.2. Microvessel density 
To assess the density of GFP+ microvessels within implanted MWD and FWM, further 
samples were co-stained using a monoclonal rat anti-mouse antibody against the endothelial 
cell marker CD31 (1:100; Dianova, Hamburg, Germany) and a polyclonal goat antibody  
against GFP (1:200; Rockland Immunochemicals, Limerick, PA, USA) while a goat anti-rat-
IgG Alexa555 (1:200; Life Technologies, Ober-Olm, Germany) and a biotinylated donkey 
anti-goat antibody (1:20; Dianova) served as secondary antibodies. The biotinylated antibody 
was detected by streptavidin-Alexa488 (1:50; Life Technologies) and cell nuclei were stained 
with Hoechst 33342 (2 µg/mL; Sigma-Aldrich). This co-staining (Figures 19A-C) allowed the 
detection of GFP+ microvessels, which originated from the seeded ad-MVF of GFP+ C57BL/6 
donor mice, within GFP- C57BL/6 recipient animals.  
 
 




microvessels in ad-MVF-seeded MWD on day 
14 after implantation into a full-thickness skin defect within a dorsal skinfold chamber of a GFP 
-
 C57BL/6 
recipient mouse. C = overlay of A (showing CD31
+
 microvessels) and B (showing GFP
+
 microvessels originating 
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Hence, the density of CD31+ (mm-2) microvessels as well as the fraction of CD31+/GFP+ 
microvessels (%) could be quantitatively analyzed within the matrices on day 14 after 
implantation. In experimental section 2, the density of CD31+ microvessels, which was 
assessed within 20 randomly selected ROIs within ad-MVF-seeded MWD and FWM, was 
used to generate the coefficient of variation (cv). For this purpose, the standard deviation of 
the microvessel density was divided by its mean. 
 
5.4.3. Cell apoptosis and proliferation 
For the identification of apoptotic cleaved caspase-3+ (Figure 20A) and proliferating Ki67+ 
(Figure 20B) cells within the matrices, histological sections were incubated with a rabbit 
polyclonal anti-cleaved caspase-3 antibody (1:100; New England Biolabs, Frankfurt, 
Germany) and a rabbit polyclonal anti-Ki67 antibody (1:500; Abcam) as primary antibodies 
followed by a biotinylated goat anti-rabbit IgG antibody (ready-to-use; Abcam) as secondary 
antibody. The biotinylated antibody was detected by peroxidase-labeled-streptavidin (1:50; 
Sigma-Aldrich) and 3-amino-9-ethylcarbazole (Abcam) was used as chromogen. The 
sections were counterstained with Mayer’s hemalaun (Merck, Darmstadt, Germany).  
 
 
Figure 20. A, B: Immunohistochemical detection of apoptotic cleaved caspase-3
+
 (A; arrows) and proliferating 
Ki67
+
 cells (B; arrowheads) in ad-MVF-seeded FWM on day 14 after implantation into full-thickness skin defects 
within mouse dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Scale bars = 50 µm.  
 
5.4.4. Immune cell infiltration 
To assess the number of myeloperoxidase (MPO)+ neutrophilic granulocytes, MAC387+ or 
CD68+ macrophages, and CD3+ lymphocytes within the matrices (Figures 21A-C), sections 
were incubated with a rabbit polyclonal anti-MPO antibody (1:100; Abcam), a rabbit 
polyclonal anti-MAC387 antibody (1:50; Abcam) or a rabbit polyclonal anti-CD68 antibody, 
and a rabbit polyclonal anti-CD3 antibody (1:100; Abcam) as primary antibodies followed by 
a biotinylated goat anti-rabbit IgG antibody (ready-to-use; Abcam). The biotinylated antibody 
was detected by peroxidase-labeled-streptavidin (1:50; Sigma-Aldrich) and 3-amino-9-
ethylcarbazole (Abcam) was used as chromogen. The sections were counterstained with 
Mayer’s hemalaun (Merck) and the number of immune cells (mm-2) was quantitatively 
assessed in 6 randomly selected ROIs per section by means of light microscopy (BX60). 
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Figure 21. A-C: Immunohistochemical detection of MPO
+
 neutrophilic granulocytes (A, arrows), MAC387
+
 
macrophages (B, arrows), and CD3
+
 lymphocytes (C, arrows) in ad-MVF-seeded MWD on day 14 after 
implantation into full-thickness skin defects within mouse dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient 
mice.  Scale bars = 37 µm.  
 
5.5. Experimental protocol 
5.5.1. Experimental protocol 1: Characterization of ad-MVF 
In the first set of experimental, ad-MVF isolates from GFP+ C57BL/6 donor mice (n = 18), 
assigned to 6 different age groups (7, 8, 9, 10, 11, and 12 months old), were characterized. 
The volume of isolated epididymal fat from each donor mouse as well as the amount of 
isolated ad-MVF per mL adipose tissue and their average length was determined (n = 3 per 
age group). To gain further insights into the cellular composition of ad-MVF, a fraction of 
each isolate was parallelly analyzed by means of flow cytometry (n = 3 per age group). 
Furthermore, samples from all isolates (n = 18) were used to assess the ad-MVF size 
distribution. For this purpose, the length of ~ 100 randomly selected ad-MVF per isolate was 
measured.  
 
Accordingly, the following groups were investigated in this experimental section: 
 Ad-MVF of 7 months old donor animals (n = 3) 
 Ad-MVF of 8 months old donor animals (n = 3) 
 Ad-MVF of 9 months old donor animals (n = 3) 
 Ad-MVF of 10 months old donor animals (n = 3) 
 Ad-MVF of 11 months old donor animals (n = 3) 
 Ad-MVF of 12 months old donor animals (n = 3) 
 
5.5.2. Experimental protocol 2: MWD vs. FWM 
In the second set of experiments, samples of both non-seeded MWD (n = 3) and FWM (n = 
3) were prepared and their surface morphologies were characterized by means of scanning 
electron microscopy. Additionally, MWD (n = 3) and FWM (n = 3) were prepared to analyze 
their fiber thickness, fiber length, and interfiber distance in vitro using HE-staining. To assess 
the cv of the microvessel density within ad-MVF-seeded MWD (n = 3) and FWM (n = 3), the 
A B C
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matrices were seeded with a comparable number of ~ 15.000 ad-MVF and analyzed by 
means of light microscopy.  
 
For in vivo analyses, non-seeded MWD (n = 8) and FWM (n = 8) as well as ad-MVF-seeded 
MWD (n = 11) and FWM (n = 11) were implanted into full-thickness skin defects within dorsal 
skinfold chambers of 38 GFP- C57BL/6 recipient mice. To assess epithelialization and 
vascularization of the matrices, the mice were repetitively analyzed by means of 
stereomicroscopy and intravital fluorescence microscopy on day 0 (day of implantation) as 
well as 3, 6, 10, and 14 (Figure 22). At the end of the 2-week observation period, the animals 
were sacrificed by means of cervical dislocation and the dorsal skinfold chamber 
preparations were processed for histological and immunohistochemical analyses of 
microvessel density, collagen content, apoptotic cell death and proliferation, epithelialization, 
and immune cell infiltration. For additional immunohistochemical analyses at an earlier time 
point, animals of ad-MVF-seeded matrices (n = 3 per group) were already sacrificed on day 6 
after implantation. 
 
Accordingly, the following groups were investigated in this experimental section: 
 Non-seeded, non-implanted MWD (control group, n = 3)  
 Non-seeded, non-implanted FWM (n = 3)  
 Non-seeded, implanted MWD (control group, n = 8) 
 Non-seeded, implanted FWM (n = 8) 
 Ad-MVF-seeded, non-implanted MWD (control group, n = 3)  
 Ad-MVF-seeded, non-implanted FWM (n = 3)  
 Ad-MVF-seeded, implanted MWD (control group, n = 11)  
 Ad-MVF-seeded, implanted FWM (n = 11)  
 
 
Figure 22. Schematic outline of the experimental protocol used for experimental protocols 2, 3, and 4. 
 
Day - 2 Day 0 Day 3 Day 6 Day 10 Day 14
Creation of full-thickness skin defects and 
filling with Integra® matrices
Dorsal skinfold chamber
preparation
Repetitive stereomicroscopy and intravital 
fluorescence microscopy
Samples for histology and 
immunohistochemistry
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5.5.3. Experimental protocol 3: Ad-MVF seeding density 
In the third set of experiments, ad-MVF were isolated from 8 GFP+ donor mice and seeded 
onto MWD in a high density (HD; ~ 15.000 ad-MVF; n = 8), a medium density (MD; ~ 10.000 
ad-MVF; n = 8), and a low density (LD: ~ 5.000 ad-MVF; n = 8). Importantly, ~ 15.000 ad-
MVF represent the number of fragments for seeding of MWD used in the identical setting of 
previous studies [FRUEH et al., 2017]. Therefore, the HD group served as a control group. All 
seeded matrices were subsequently used to fill full-thickness skin defects of 24 GFP- 
C57BL/6 recipient mice. According to Figure 22, repetitive stereomicroscopy and intravital 
fluorescence microscopy were used to assess the epithelialization, hemorrhage formation, 
and vascularization of the matrices over time. Furthermore, photoacoustic images of 3 
matrices per group were acquired on day 0 and 14 to detect the sO2 levels within the seeded 
matrices. On day 14, the mice were sacrificed by means of cervical dislocation and the 
dorsal skinfold chamber preparations were processed for histological and 
immunohistochemical analyses of microvessel density, collagen content, immune cell 
infiltration, and epithelialization. 
 
Accordingly, the following groups were investigated in this experimental section: 
 Ad-MVF-seeded, implanted MWD (HD, control group, n = 8)  
 Ad-MVF-seeded, implanted MWD (MD, n = 8)  
 Ad-MVF-seeded, implanted MWD (LD, n = 8)  
 
5.5.4. Experimental protocol 4: Ad-MVF vs. SVF single cells 
In the fourth set of experiments, epididymal donor fat tissue was harvested from 8 GFP+ 
C57BL/6 donor mice to subsequently analyze the viability and composition of SVF single 
cells (n = 4) and ad-MVF (n = 4) by means of fluorescence microscopy and flow cytometry in 
vitro.  
 
For in vivo analyses, both SVF single cells and ad-MVF were isolated from adipose tissue of 
8 GFP+ C57BL/6 donor mice and subsequently seeded onto 16 MWD samples. These 
matrices were then implanted into full-thickness skin defects within dorsal skinfold chambers 
of 16 GFP- C57BL/6 recipient mice. According to Figure 22, repetitive stereomicroscopy and 
intravital fluorescence microscopy were used to assess the epithelialization, hemorrhage 
formation, and vascularization of the matrices over time. On day 14, the mice were sacrificed 
by means of cervical dislocation and the dorsal skinfold chamber preparations were 
processed for histological and immunohistochemical analyses of microvessel density, 
collagen content, and epithelialization. 
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Accordingly, the following groups were investigated in this experimental section: 
 Ad-MVF-seeded, implanted MWD (control group, n = 8)  
 SVF-seeded, implanted MWD (n = 8) 
 
5.5.5. Experimental protocol 5: Enox treatment 
In the fifth set of experiments, ad-MVF were isolated from 3 enox- (8 mg/kg dissolved in 100 
µL 0.9 % NaCl, subcutaneously (s.c.)) and 3 vehicle-treated (100 µL 0.9 % NaCl, s.c.) GFP+ 
C57BL/6 donor mice and seeded onto 16 MWD samples. Thereafter, the matrices were 
implanted into full-thickness skin defects of enox- and vehicle-treated GFP- C57BL/6 
recipient mice. Importantly, the used enox dosage of 8 mg/kg corresponded to the clinically 
used dose of 0.5 mg/kg for thromboprophylactic treatment of hospitalized patients 
[CHOUSSAT et al., 2002; SANDERINK  et al., 2002; REAGAN-SHAW et al., 2008; RONDINA et al., 
2010]. After the implantation of ad-MVF-seeded MWD, the recipient animals were 
continuously treated daily with either enox (8 mg/kg dissolved in 100 µL 0.9 % NaCl) or 
vehicle (100 µL 0.9 % NaCl) throughout the observation period of 2 weeks. According to 
Figure 23, repetitive stereomicroscopy and intravital fluorescence microscopy were used to 




Figure 23. A: GFP 
+
 donor mice were pretreated once daily with enox or vehicle for 48 hours. B: Ad-MVF were 
harvested from the epididymal fat pads of the donor animals, seeded onto MWD, and implanted into full-thickness 
skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 mice. C: Enox-treated ad-MVF were exclusively 
transferred into recipient mice, which received daily s.c. injections of enox from the day of chamber preparation 
until the end of the in vivo experiments. Accordingly, vehicle-treated ad-MVF were exclusively transferred into 
recipient mice, which received daily injections of vehicle. The matrices were microscopically analyzed on day 0 
(day of implantation), 3, 6, 10, and 14. D: At the end of the 2-week observation periods, the dorsal skinfold 

















daily s.c. administration of enox (8 mg/kg) or
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On day 14, a tail vein bleeding test was performed to confirm the anti-coagulative effect of 
enox. Thereafter, the mice were sacrificed and the dorsal skinfold chamber preparations 
were processed for histological and immunohistochemical analyses of microvessel density, 
collagen content, and epithelialization (Figure 23). 
 
Accordingly, the following groups were investigated in this experimental section: 
 Ad-MVF-seeded, vehicle-treated implanted MWD (control group, n = 8)  
 Ad-MVF-seeded, enox-treated implanted MWD (n = 8)  
 
5.6. Statistical analyses 
All data were first tested for normal distribution and equal variance. Differences between the 
groups of experimental section 1, 2, 4, and 5 were analyzed by the unpaired Student’s t-test 
(SigmaPlot 11.0; Jandel Corporation, San Rafael, CA, USA). In section 3, differences 
between the groups were analyzed by ANOVA followed by the Student-Newman-Keuls post 
hoc test (SigmaPlot) to compensate for the α-error according to Bonferoni probabilities when 
comparing multiple groups. All values are expressed as mean ± standard error of the mean 
(SEM). Statistical significance was accepted for a value of p < 0.05. 
 




6.1. Characterization of ad-MVF 
6.1.1. Length distribution 
Epididymal fat pads were separately harvested from GFP+ donor animals of 6 different age 
groups. Interestingly, no significant differences in the available volume of adipose tissue 
were found between 7 - 12 months old donor animals (Figure 24A). Accordingly, ~ 1.4 mL of 
such fat tissue could be harvested from all mice for the following isolation of ad-MVF. The 
isolation process further revealed that ~ 40.000 ad-MVF could be isolated from 1 mL adipose 
tissue (Figure 24B). Microscopic analyses further showed a comparable average ad-MVF 
length of ~ 38 µm in all age groups (Figure 25A). Of interest, ~ 70 % of the isolated ad-MVF 




Figure 24. A, B: Volume of available epididymal adipose tissue (mL) (A) and number of isolated ad-MVF (ad-
MVF per mL adipose tissue) (B) from 7, 8, 9, 10, 11, and 12 months old GFP
+
 C57BL/6 donor mice (n = 3 per 




Figure 25. A: Length of ad-MVF (µm) from 7, 8, 9, 10, 11, and 12 months old GFP
+
 donor mice (n = 3 per group). 
Mean ± SEM. B: Length distribution of ad-MVF (%) from 7-12 months old GFP
+
 C57BL/6 donor mice (n = 18). 
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6.1.2. Cellular composition 
A comparable cellular composition of ad-MVF from donor mice of different ages was 
revealed by means of flow cytometry. The ad-MVF contained 21 - 30 % CD31+ endothelial 
cells, 15 - 20 %  α-SMA+ perivascular cells, and 5 - 10 % ASAM+ adipocytes as well as 45 - 
58 %, 7 - 10 %, and 6 - 11 % cells expressing the stromal/stem cell surface markers CD29, 
CD117, and CD90, respectively (Table 1). 
 
Age (months) CD31 α-SMA ASAM CD29 CD117 CD90 
7 30.0 ± 1.8 16.1 ± 1.4 9.1 ± 0.9 48.3 ± 3.6 9.1 ± 1.0 7.9 ± 0.6 
8 27.4 ± 1.6 19.8 ± 1.8 5.1 ± 0.3 51.0 ± 2.5 7.2 ± 1.1 6.4 ± 1.1 
9 25.7 ± 0.9 15.5 ± 1.6 7.8 ± 1.0 50.3 ± 3.7 7.1 ± 0.5 7.2 ± 0.6 
10 23.9 ± 5.1 14.8 ± 2.5 9.7 ± 1.7 57.7 ± 2.8 9.8 ± 1.4 10.8 ± 1.5 
11 20.8 ± 0.5 16.4 ± 2.1 8.4 ± 0.5 44.9 ± 5.1 8.0 ± 0.8 6.9 ± 0.7 
12 24.7 ± 4.7 20.1 ± 1.7 6.6 ± 1.7 51.2 ± 7.4 7.9 ± 1.2 8.6 ± 1.9 
 
Table 1. Cellular expression (%) of CD31, α-SMA, ASAM, CD29, CD117, and CD90 in ad-MVF isolated from the 
epididymal fat pads of 7-12 months old GFP
+
 C57BL/6 donor mice (n = 3 per group), as assessed by flow 
cytometric analysis. Mean ± SEM. 
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6.2. MWD vs. FWM 
6.2.1. Non-seeded MWD and FWM 
6.2.1.1. Surface morphology 
According to 5.2.2., both non-implanted, non-seeded MWD and FWM were first 
characterized by means of scanning electron microscopy in order to observe possible 
variations in their surface morphologies due to varying sample preparations. Of interest, this 




Figure 26. A-F: Scanning electron microscopy of non-seeded, non-implanted MWD (A-C) and FWM (D-F) directly 
after sample preparation. B, E: Higher magnifications of pore-rich areas (closed frames in A, D) of MWD (B) and 
FWM (E). C, F: Higher magnifications of areas with low porosity and higher material density (dotted frames in A, 
D) of MWD (C) and FWM (F) samples. Scale bars: A, D = 150 µm; B, C, E, F = 25 µm.   
 
Whereas the sheet-like MWD (Figures 26A-C) exhibited a mostly planar surface, the gel-like 
FWM (Figures 26D-F) presented a more fissured and irregular surface. Although both matrix 
types showed slight differences in their overall morphology, higher magnifications revealed 
that the random distribution of pore-rich areas with lower material density (Figures 26B and 
E) and areas of low porosity and a higher material density (Figures 26C and F) was 
comparable in both matrices.  
 
To further assess the effect of varying sample preparations on the material properties of 
MWD and FWM, HE-stained histological sections were analyzed. It could be shown that fiber 
thickness (~ 2 µm), fiber length (~ 120 µm), and interfiber distance (~ 45 µm) were 
comparable in both matrices, as quantitatively assessed by means of light microscopy 
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Figure 27. A, B: HE-stained sections of MWD (A) and FWM (B) directly after sample preparation. Scale bars = 40 
µm. C-E: Fiber thickness (µm) (C), fiber length (µm) (D), and interfiber distance (µm) (E) of MWD (white bars, n = 
3) and FWM (black bars, n = 3), as assessed by quantitative histological analyses. Mean ± SEM. 
 
6.2.1.2. Epithelialization 
For in vivo analyses, the matrices were implanted into full-thickness skin defects within 
dorsal skinfold chambers of GFP- C57BL/6 recipient mice and repetitively analyzed for 2 
weeks. Epi-illumination stereomicroscopy was used to quantify the epithelialization of MWD 
and FWM over time (Figures 28A-G). This analysis revealed a comparable epithelialization of 
both matrices. To further confirm these findings, additional immunohistochemical analyses 
were performed. These analyses showed that a cytokeratine+ epithelial layer covered 29.1 ± 
7.7 % (MWD) and 37.8 ± 6.7 % (FWM) of the matrices´ surfaces on day 14 after implantation 
into full-thickness skin defects within dorsal skinfold chambers of C57BL/6 recipient mice 
(Figures 29A and B). 
 
 
Figure 28. A-F: Stereomicroscopic images of full-thickness skin defects in dorsal skinfold chambers of GFP 
-
 
C57BL/6 recipient mice filled with either MWD (A-C) or FWM (D-F) directly after implantation (A, D) as well as on 
day 6 (B, E) and 14 (C, F). Closed lines = matrix borders. Dotted lines = non-epithelialized matrix areas. Scale 
bars = 1.5 mm. G: Epithelialization (% of total matrix surface) of implanted MWD (white bars, n = 8) and FWM 
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Figure 29. A, B: Immunohistochemical detection of the cytokeratine
+
 epithelial layer (arrows) covering MWD (A) 
and FWM (B) on day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of 
C57BL/6 recipient mice. Scale bars = 145 µm.  
 
6.2.1.3. Vascularization and incorporation 
HE-stained sections revealed a comparable ingrowth of vascularized granulation tissue into 
the pores of MWD and FWM on day 14 after implantation into full-thickness skin defects of 
C57BL/6 recipient mice (Figures 30A and B). Of interest, the infiltrated granulation tissue was 
mainly observed in the border zones of both matrices whereas their centers only contained a 
few migrated single cells. Additionally, a relatively low collagen content was found in both 
MWD and FWM when compared to normal skin (Figures 31A-D), indicating a rather poor 
incorporation into the surrounding host tissue on day 14. In line with these findings, only a 




Figure 30. A, B: HE-stained sections of non-seeded MWD (A) and FWM (B) on day 14 after implantation into full-
thickness skin defects within dorsal skinfold chambers of C57BL/6 recipient mice. The ingrowth of granulation 
tissue is found primarily in the border zones of the matrices (A, B; asterisks). Broken lines = matrix borders. Scale 
bars = 300 µm. 
 
 
Figure 31. A-C: Sirius red-stained sections of normal skin (A) as well as non-seeded MWD (B) and FWM (C) on 
day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 
recipient mice. Scale bars = 40 µm. D: Total collagen ratio (matrix/skin) of implanted MWD (white bars, n=8) and 
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Figure 32. A, B: Immunofluorescent detection of CD31
+
 microvessels (arrows) within MWD (A) and FWM (B) on 
day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of C57BL/6 recipient 
mice. Scale bars = 40 µm. C: Microvessel density (mm
-2
) of implanted MWD (white bars, n = 8) and FWM (black 
bars, n = 8), as assessed by quantitative immunohistochemical analysis. Mean ± SEM. 
 
6.2.1.4. Biocompatibility 
Immunohistochemistry was used to assess the number of MPO+ neutrophilic granulocytes, 
MAC387+ macrophages, and CD3+ lymphocytes infiltrating non-seeded MWD and FMW on 
day 14 after implantation (Figures 33A-C). All three types of immune cells comparably 
infiltrated the matrices. Neutrophilic granulocytes represented the majority of the detected 
immune cells. Their density (~ 200 mm-2) was markedly higher when compared to those of 
infiltrated macrophages (~ 40 mm-2) and lymphocytes (~ 10 mm-2). These findings indicate a 
comparable in vivo biocompatibility of both matrices. 
 
 
Figure 33. A-C: MPO
+











) (C) within MWD (white bars, n = 8) and FWM (black bars, n = 8) on day 14 after implantation 
into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice, as assessed by 
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6.2.2. Ad-MVF-seeded MWD and FWM 
6.2.2.1. Ad-MVF distribution  
As a flowable matrix, FWM may allow a more homogeneous distribution of ad-MVF during 
sample preparation when compared to MWD. To test this hypothesis, MWD and FWM 
samples were seeded with an identical number of ~ 15,000 ad-MVF. Of interest, HE-stained 
sections (Figures 34A and B) of the matrices revealed that the ad-MVF were exclusively 
localized on the surface of MWD whereas ad-MVF in FWM exhibited a more homogeneous 
distribution. To further confirm these findings, the distribution of CD31+ microvessels (Figures 
34C and D) was assessed throughout the entire matrix. The calculated cv of the microvessel 
density was lower within FWM (Figure 34E) when compared to MWD. Accordingly, the inter-
fragment distance, i.e. the distance in between individual ad-MVF, was 15-fold higher in 
FWM when compared to MWD (Figure 34F).  
 
 
Figure 34. A-D: HE-stained and immunofluorescent sections of MWD (A, C) and FWM (B, D) directly after 
seeding within ad-MVF. Broken line = matrix border. Arrows = ad-MVF. The immunofluorescent sections were 
stained with an antibody against CD31 (C, D; red) and Hoechst 33342 (C, D; blue). Scale bars = 100 µm. E, F: Cv 
(E) and inter-fragment distance (µm) (F) of ad-MVF-seeded MWD (white bars; n = 3) and FWM (black bars; n = 
3). Mean ± SEM. *p < 0.05 vs. MWD. 
 
6.2.2.2. Vascularization and incorporation 
The dorsal skinfold chamber model was used to repetitively analyze the in vivo 
vascularization and incorporation of ad-MVF-seeded MWD and FWM by means of intravital 
fluorescence microscopy. The analysis of both matrices revealed that seeded ad-MVF 
reassembled into new microvascular networks and formed interconnections with the 
microvasculature of the surrounding host tissue. This resulted in an early onset of blood 
perfusion (Figures 35A-F) on day 3 after implantation. Interestingly, both kinetics and extent 
of this process were significantly diminished in ad-MVF-seeded FWM. When compared to 
ad-MVF-seeded MWD, FWM exhibited a reduced number of perfused ROIs between day 10 
and 14 as well as a lower functional microvessel density on day 14 (Figures 35G and H). 
Analyzed microhemodynamic parameters in both groups revealed a decreasing diameter of 
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shear rate progressively increased in microvessels of ad-MVF-seeded MWD and FWM 
(Table 2).  
 
 
Figure 35. A-F: Intravital fluorescence microscopy (blue light epi-illumination with 5 % FITC-labeled dextran 
150,000 i.v.) of implanted, ad-MVF-seeded MWD (A-C) and FWM (D-F) on day 14 after implantation into full-
thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Broken line = matrix 
border. Arrows = perfused microvessels. B, E = inserts in A, D. C, F = inserts in B, E. Scale bars: A, D = 2 mm; B, 
E = 400 µm; C, F = 100 µm. G, H: Perfused ROIs (%) (G) and functional microvessel density (cm/cm
2
) (H) of ad-
MVF-seeded MWD (white bars; n = 8) and FWM (black bars; n = 8). Mean ± SEM. *p < 0.05 vs. MWD. 
 
Although not proven to be significant at each time point, the diameter, centerline RBC 
velocity, and wall shear rate of microvessels within FWM were reduced when compared to 
MWD (Table 2). After 14 days, analyses of HE-stained sections showed that all pores of ad-
MVF-seeded MWD were completely filled with a dense vascularized granulation tissue 
whereas FWM only contained a few infiltrated single cells within its center zones (Figures 
36A-D). Additional immunohistochemical analyses revealed that ad-MVF-seeded FWM 
contained a significantly lower number of CD31+ microvessels (~ 120 mm-2) when compared 
to MWD (~ 210 mm-2) (Figures 37A-C). CD31/GFP co-staining revealed that ~ 93 % and ~ 80 
% of all detected microvessels in MWD and FWM originated from GFP+ ad-MVF (Figures 







































































 d0 d3 d6 d10 d14 
Diameter (µm) 
MWD - 27.5 ± 8.6 27.4 ± 2.6   22.3 ± 2.7 18.1 ± 1.5 
FWM - 23.3 ± 5.2 32.9 ± 5.4 16.8 ± 0.1* 14.7 ± 0.9 
Centerline RBC velocity (µm/s) 
MWD - 150.6 ± 65.9  428.9 ± 111.8 696.4 ± 66.0 643.3 ± 79.2 
FWM -   62.5 ± 25.5  101.1 ± 37.6 420.3 ± 89.7 461.9 ± 60.7 
Wall shear rate (s
-1
) 
MWD - 59.6 ± 21.5  136.4 ± 42.7 268.7 ± 37.4 292.9 ± 51.6 
FWM -   19.7 ± 7.8   25.8 ± 11.2* 203.3 ± 44.4 250.5 ± 24.3 
 
Table 2. Diameter (µm), centerline RBC velocity (µm/s), and wall shear rate (s
-1
) of blood vessels within ad-MVF-
seeded MWD and FWM directly (d0) as well as on day 3, 6, 10, and 14 after implantation into full-thickness skin 
defects within dorsal skinfold chambers of GFP
-
 C57BL/6 recipient mice. Mean ± SEM. *p < 0.05 vs. MWD. 
 
 
Figure 36. A-D: HE-stained sections of ad-MVF-seeded MWD (A, B) and FWM (C, D) on day 14 after 
implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. 
Broken lines = matrix borders. Asterisks = border zones. Arrows = panniculus carnosus muscle of the dorsal 
skinfold chamber preparation. B, D = insert in A, C. Scale bars: A, C = 350 µm; B, D = 50 µm. 
 
 
Figure 37. A, B: Immunohistochemical detection of CD31
+
 microvessels (arrows) in ad-MVF-seeded MWD (A) 
and FWM (B) on day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 
C57BL/6 recipient mice. Scale bars = 30 µm. C: Microvessel density (mm
-2
) of ad-MVF-seeded MWD (white bar; 
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Figure 38. A, B: Immunohistochemical detection of microvessels in ad-MVF-seeded FWM on day 14 after 
implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. 
Arrows = CD31 
+
 (red) / GFP 
+
 (green) microvessels. Arrowhead = CD31 
+
 / GFP 
-
 microvessel. C: Merge of A 
and B. Scale bars = 15 µm. D: GFP 
+
 microvessels (%) in ad-MVF-seeded MWD (white bar; n = 8) and FWM 
(black bar; n = 8). Mean ± SEM. *p < 0.05 vs. MWD.  
 
Additional Sirius red-staining was used to detect mature collagen type I fibers by their 
reddish appearance under polarized light. This analysis revealed a lower collagen ratio in 
FWM when compared to MWD (Figures 39A-D). 
 
 
Figure 39. A-C: Sirius red-stained sections of normal skin (A) as well as ad-MVF-seeded MWD (B) and FWM (C) 
on day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 
recipient mice. Scale bars = 125 µm. D: Total collagen ratio (matrix/skin) of ad-MVF-seeded MWD (white bar; n = 
8) and FWM (black bar; n = 8). Mean ± SEM. *p < 0.05 vs. MWD. 
 
6.2.2.3. Epithelialization 
Repetitive epi-illumination microscopy showed a diminished epithelialization of FWM 
between day 6 and 14 when compared to MWD (Figures 40A-G). Immunohistochemical 
detection of the cytokeratine+ epithelial layer further revealed that 74.0 ± 13.5 % of the MWD 
surface was covered with a cytokeratine+ epithelial layer, whereas only 39.9 ± 4.3 % of the 
FWM surface exhibited an epithelial coverage on day 14 after implantation into full-thickness 
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Figure 40. A-F: Stereomicroscopic images of full-thickness skin defects in dorsal skinfold chambers of GFP 
-
 
C57BL/6 mice filled with either ad-MVF-seeded MWD (A-C) or FWM (D-F) directly after implantation (A, D) as 
well as on day 6 (B, E) and 14 (C, F). Closed lines = matrix borders. Dotted lines = non-epithelialized areas. Scale 
bars = 1.5 mm. G: Epithelialization (% of total matrix area) of implanted ad-MVF-seeded MWD (white bars; n = 8) 
and FWM (black bars; n = 8). Mean ± SEM. *p < 0.05 vs. MWD. 
 
 
Figure 41. A, B: Immunohistochemical detection of the cytokeratine
+
 epithelial layer (arrows) covering MWD (A) 
and FWM (B) on day 14 after implantation into full thickness skin defects within dorsal skinfold chambers of GFP 
-
 
C57BL/6 recipient mice. Scale bars = 145 µm. 
 
6.2.2.4. Apoptotic cell death and proliferation 
Immunohistochemical analyses further revealed that ad-MVF-seeded FWM contained a 
significantly higher number of cleaved caspase-3+ apoptotic cells (5.3 ± 0.8 %) as well as a 
lower number of proliferating Ki67+ cells (48.8 ± 21.6 %) when compared to ad-MVF-seeded 
MWD (3.1 ± 1.0 % and 81.1 ± 2.0 %) on day 6 (Figures 42A-D).  
 
 
Figure 42. A-D: Immunohistochemical detection of apoptotic cleaved caspase-3
+
 (A, B; arrows) and proliferating 
Ki67
+
 cells (C, D; arrows) in ad-MVF-seeded MWD (A, C) and FWM (B, D) on day 6 (A, C) and 14 (B, D) after 
implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. 
Scale bars = 50 µm.  
 
However, at the end of the 14-day observation period, both matrices exhibited comparable 
numbers of 1.5 ± 0.3 % (MWD) and 1.2 ± 0.1 % (FWM) cleaved caspase-3+ apoptotic cells 
as well as 10.4 ± 1.3 % (MWD) and 11.7 ± 2.1 % (FWM) Ki67+ proliferating cells. 
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6.3. Ad-MVF seeding density 
6.3.1. Vascularization and incorporation 
In this experimental section, MWD was seeded with three different densities (HD, MD, LD) of 
GFP+ ad-MVF to determine the lowest density needed to maintain a sufficient vascularization 
and incorporation of the matrix. Full-thickness skin defects within dorsal skinfold chambers of 
GFP- C57BL/6 mice were filled with the seeded MWD to repetitively visualize and analyze its 
vascularization by means of intravital fluorescence microscopy over time (Figures 43A-I). In 
all groups, an onset of blood perfusion was detected on day 6 after implantation (Figure 43J). 
Throughout the observation time of 14 days, the density of perfused microvessels 
continuously increased (Figure 43K). This was associated with typical signs of vascular 
maturation and remodeling, i.e. the reduction of diameters as well as the increase of 
centerline RBC velocities and wall shear rates of individual microvessels within the matrices 
(Table 3).  
 
 d0 d3 d6 d10 d14 
Diameter (µm) 
HD - - 31.5 ± 1.0 23.5 ± 1.7 17.2 ± 1.2 
MD - - 31.7 ± 1.8 24.1 ± 1.5 19.5 ± 1.4 
LD - - 28.9 ± 0.5 22.5 ± 0.6 21.2 ± 0.9 
Centerline RBC velocity (µm/s) 
HD - - 229.2 ± 51.0 450.5 ± 58.5 497.6 ± 78.9 
MD - - 176.2 ± 53.5 419.6 ± 78.3   438.8 ± 100.9 
LD - - 148.1 ± 50.7 302.5 ± 36.1 392.4 ± 66.8 
Wall shear rate (s
-1
) 
HD - - 58.8 ± 13.0 141.0 ± 17.8 243.2 ± 47.8 
MD - - 42.6 ± 11.8 137.5 ± 20.6 187.9 ± 45.1 
LD - - 41.0 ± 13.8 151.2 ± 30.3 151.2 ± 30.3 
 
Table 3. Diameter (µm), centerline RBC velocity (µm/s), and wall shear rate (s
-1
) of microvessels in HD (n = 8), 
MD (n = 8), and LD (n = 8) ad-MVF-seeded MWD on day 6, 10, and 14 after implantation into full-thickness skin 
defects within dorsal skinfold chambers of GFP
-
 C57BL/6 recipient mice, as assessed by intravital fluorescence 
microscopy and computer-assisted image analysis. Mean ± SEM.  
 
The process of vascularization was comparable in HD and MD ad-MVF-seeded matrices. 
Furthermore, no significant differences in morphological and microhemodynamic parameters 
were detected between the groups (Figures 43J and K, Table 3). LD ad-MVF-seeded 
matrices, on the other hand, showed a rather weak vascularization with lower numbers of 
perfused ROIs and a diminished functional microvessel density between day 6 and 14 
(Figures 43J and K). Matrix-induced hemorrhages correlated with the extent of 
vascularization and could be mainly seen during the early phase of microvascular network 
formation on day 6. Of interest, the hemorrhagic score of HD and MD ad-MVF-seeded MWD 
was higher on day 6 and 10 when compared to LD ad-MVF-seeded MWD. 
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Figure 43. A-I: Intravital fluorescence microscopy (blue light epi-illumination, 5 % FITC-labeled dextran) of HD (A, 
D, G), MD (B, E, H), and LD (C, F, I) ad-MVF-seeded MWD on day 14 after implantation into full-thickness skin 
defects within dorsal skinfold chambers of GFP
-
 C57BL/6 mice. A-C = overview of the chamber observation 
window. D-F = higher magnification of inserts in A-C. G-I = higher magnification of inserts in D-F. Note that the 
HD and MD ad-MVF-seeded matrices exhibit an improved vascularization when compared to LD ad-MVF-seeded 
ones. Scale bars: A-C = 2.5 mm; D-F = 500 µm; G-I = 125 µm. J, K: Perfused ROIs (%) (J) and functional 
microvessel density (cm/cm²) (K) of HD (black circles, n = 8), MD (grey circles, n = 8), and LD (white circles, n = 
8) ad-MVF-seeded MWD, as assessed by intravital fluorescence microscopy and computer-assisted image 
analysis. Means ± SEM. *p < 0.05 vs. HD ad-MVF-seeded MWD; 
#
p < 0.05 vs. MD ad-MVF-seeded MWD. 
 
Additional photoacoustic imaging was used to first detect oxygenation of ad-MVF-seeded 
matrices in vitro immediately after their seeding (Figures 44A-F). According to the different 
seeding densities, LD ad-MVF-seeded, non-implanted matrices contained significantly lower 
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sO2 levels when compared to HD ad-MVF-seeded samples (Figure 44G). Fourteen days 
after implantation, the oxygenation levels were markedly increased when compared to those 
directly after seeding. Noteworthy, LD ad-MVF-seeded matrices exhibited reduced sO2 levels 
when compared to HD ad-MVF-seeded matrices (Figures 44H-M). In line with the intravital 
microscopic findings, MD and HD groups were comparable (Figures 44G and N).  
 
 
Figure 44. A-F: B-mode ultrasound (A, C, E) and photoacoustic imaging (B, D, F) of freshly HD (A, B), MD (C, D) 
and LD (E, F) ad-MVF-seeded MWD directly after the seeding procedure. Scale bars = 600 µm. Red areas = high 
oxygenation. Blue areas = low oxygenation. G: sO2 (%) within freshly HD (black bar, n = 3), MD (grey bar, n = 3), 
and LD (white bar, n = 3) ad-MVF-seeded MWD. H-M: B-mode ultrasound (H, J, L) and photoacoustic imaging (I, 
K, M) of HD (H, I), MD (J, K) and LD (L, M) ad-MVF-seeded MWD on day 14 after implantation into full-thickness 
skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Red areas = high oxygenation. 
Blue areas = low oxygenation. Black areas = no oxygenation. Scale bars = 600 µm. N: sO2 (%) within HD (black 
bar, n = 3), MD (grey bar, n = 3), and LD (white bar, n = 3) ad-MVF-seeded MWD on day 14 after implantation. 
Means ± SEM. *p < 0.05 vs. HD ad-MVF-seeded MWD. 
 
On day 14 after implantation, HE-stained sections revealed that LD ad-MVF-seeded matrices 
exhibited a dense vascularization exclusively in the border zones and only a few invaded 
single cells in their center (Figures 45E and F). In contrast, HD and MD ad-MVF-seeded 
matrices exhibited a dense vascularized granulation tissue throughout the entire matrix 
(Figures 45A-D). Additional analyses of Sirius red-stained sections showed that LD ad-MVF-
seeded matrices contained a reduced amount of mature collagen fibers when compared to 
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Figure 45. A-F: HE-stained sections of HD (A, B), MD (C, D), and LD (E, F) ad-MVF-seeded MWD on day 14 
after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 mice. Broken 
lines = matrix borders. Asterisks = border zones. Arrows = panniculus carnosus muscle. B, D, F = inserts in A, C, 
E. Scale bars A, C, E = 200 µm; B, D, F = 50 µm. G-J: Sirius red-stained sections of normal skin (G) as well as 
HD (H), MD (I), and LD (J) ad-MVF-seeded MWD. Scale bars = 45 µm. K: Total collagen ratio (matrix/skin) within 
HD (black bar, n = 8), MD (grey bar, n = 8) and LD (white bar, n = 8) ad-MVF-seeded MWD. Means ± SEM. *p < 
0.05 vs. HD ad-MVF-seeded MWD; 
#
p < 0.05 vs. MD ad-MVF-seeded MWD. L-N: CD31
+
 microvessels (arrows) 
in HD (L), MD (M), and LD (N) ad-MVF-seeded matrices. Scale bars = 45 µm. O: Microvessel density (mm
-2
) 
within HD (black bar, n = 8), MD (grey bar, n = 8), and LD (white bar, n = 8) ad-MVF-seeded MWD. Means ± 
SEM. *p < 0.05 vs. HD ad-MVF-seeded MWD; 
#









 microvessels.  Scale bars = 45 
µm. S: GFP 
+
 microvessels (%) within HD (black bar, n = 8), MD (grey bar, n = 8) and LD (white bar, n = 8) ad-
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In line with the intravital fluorescence microscopic findings, the density of CD31+ 
microvessels was significantly reduced in LD ad-MVF-seeded matrices when compared to 
HD and MD ad-MVF-seeded matrices (Figures 45L-O). Furthermore, the 
immunohistochemical detection of CD31+/GFP+ vessels revealed that ~ 90 % of all 
microvessels originated from the GFP+ ad-MVF in all three experimental groups (Figures 
45P-S). 
 
6.3.2. Immune cell infiltration 
Immunohistochemical detection of MPO+ neutrophilic granulocytes, CD68+ macrophages, 
and CD3+ lymphocytes (Figures 46A-C) showed that the infiltration of all three immune cell 
types was markedly reduced in LD ad-MVF-seeded matrices when compared to HD and MD 
ad-MVF-seeded matrices.  
 
 
Figure 46. A-C: MPO
+











) (C) within HD (black bars, n = 8), MD (grey bars, n = 8), and LD (white bars, n = 8) ad-MVF-
seeded MWD on day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP
-
 
C57BL/6 mice. Means ± SEM. *p < 0.05 vs. HD ad-MVF-seeded MWD; 
#
p < 0.05 vs. MD ad-MVF-seeded MWD. 
 
6.3.3. Epithelialization  
The repetitive stereomicroscopic analysis of matrix epithelialization revealed a comparable 
epithelialization of HD (Figures 47A and D) and MD (Figures 47B and E) ad-MVF-seeded 
MWD, whereas the epithelialized surface of LD (Figures 47C and F) ad-MVF-seeded MWD 
was significantly reduced on day 10 and 14 (Figures 47C, F, and G).  These findings were 
further confirmed by immunohistochemical staining of the epithelial layer on day 14 after 
implantation (Figures 48A-D). Accordingly, both HD (Figure 48A) and MD (Figure 48B) ad-
MVF-seeded matrices exhibited a comparable cytokeratine+ epithelial layer, covering 75.0 ± 
6.5 % and 66.0 ± 7.7 % of their surfaces, whereas LD (Figure 48C) ad-MVF-seeded matrices 
































































































Figure 47. A-F: Stereomicroscopic images of implanted HD (A, D), MD (B, E), and LD (C, F) ad-MVF-seeded 
MWD directly (A-C) as well as on day 14 (D-F) after implantation into full-thickness skin defects within dorsal 
skinfold chambers of GFP
-
 C57BL/6 recipient mice. Scale bars = 750 µm. G: Epithelialization (% of total matrix 
surface) of HD (black circles, n = 8), MD (grey circles, n = 8), and LD (white circles, n = 8) ad-MVF-seeded MWD, 
as assessed by planimetric analysis of stereomicroscopic images. Means ± SEM. *p < 0.05 vs. HD ad-MVF-
seeded MWD; 
#
p < 0.05 vs. MD ad-MVF-seeded MWD. 
 
 
Figure 48. A-C: Immunohistochemical detection of the cytokeratine
+
 epithelial layer (arrows) covering HD (A), MD 
(B), and LD (C) ad-MVF-seeded MWD
 
on day 14 after implantation into full-thickness skin defects within dorsal 
skinfold chambers of GFP
-
 C57BL/6 recipient mice. Scale bars = 0.8 mm. D: Epithelialization (% of total matrix 
diameter) of HD (black bar, n = 8), MD (grey bar, n = 8), and LD (white bar, n = 8) ad-MVF-seeded MWD, as 
assessed by immunohistochemical analysis. Means ± SEM. 
 
  

















































































R e s u l t s  | 55 
 
6.4. Ad-MVF vs. SVF single cells 
6.4.1. Viability and cellular composition  
In this experimental section it was analyzed whether the ad-MVF-based prevascularization of 
MWD is superior to the prevascularization with the SVF. After the isolation of SVF single 
cells (Figure 48A) and the ad-MVF cell-vessel suspension (Figure 48B), a viability test was 
performed to determine the cellular survival rate for both isolates prior to their seeding onto 
MWD. It could be demonstrated that 95.1 ± 1.6 % of all ad-MVF cells and only 81.8 ± 0.6 % 
(p < 0.05) of all SVF single cells were viable (Figures 48C and D). Flow cytometric analyses 
further revealed a comparable composition of both ad-MVF and SVF single cells (Table 4).   
 
 
Figure 48. A, B: Light microscopy of SVF single cells (A) and ad-MVF (B). Scale bars = 50 µm. C, D: Bb/PI 
viability staining of SVF single cells (C) and ad-MVF (D). Blue cells = Bb staining of all nuclei. Red cells = PI 
staining of dead/damaged cells. Arrows = damaged cellular fraction of SVF single cells (C) and ad-MVF (D). 
Scale bars = 50 µm. 
 
 CD31 α-SMA ASAM CD29 CD90 CD117 
SVF 34.4 ± 7.3 17.3 ± 1.2 14.4 ± 3.2 47.6 ± 4.7 10.4 ± 3.3 12.7 ± 3.3 
Ad-MVF 18.0 ± 3.2 16.4 ± 2.3 13.0 ± 1.6 47.5 ± 4.7   7.1 ± 2.3   9.2 ± 1.7 
 
Table 4. Cellular expression (%) of CD31, α-SMA, ASAM, CD29, CD90, and CD117 within SVF and ad-MVF 
isolates from the epididymal fat pads of GFP 
+
 C57BL/6 mice, as assessed by flow cytometric analysis. Mean ± 
SEM. 
 
6.4.2. Vascularization, hemorrhage formation, and incorporation 
Unlike SVF single cells that form new blood vessels de novo, ad-MVF rapidly bridge wide 
distances throughout the seeded matrices by interconnecting to each other. Because of this, 
ad-MVF-seeded matrices showed blood-perfused ROIs within their center zones earlier than 
SVF single cell-seeded ones. Hence, center and border zones of the matrices were analyzed 
separately in the fourth experimental section. Repetitive intravital fluorescence microscopy of 
implanted MWD (Figures 49A-F) revealed that first blood-perfused microvessels could be 
observed on day 6 after implantation (Figures 49G and H). Throughout the following 
observation period, the density of microvessels increased in both groups. Of interest, ad-
MVF-seeded matrices exhibited a higher fraction of perfused ROIs and a higher functional 
microvessel density within their border zones when compared to SVF-seeded MWD on day 
14 (Figures 49G and I). This divergent degree of vascularization was even more pronounced 
within the center zones of the matrices (Figures 49H and J). Whereas ad-MVF-seeded MWD 
A B C D
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was completely vascularized on day 14, SVF-seeded matrices only exhibited 25 % perfused 
ROIs. Furthermore, the functional microvessel density of SVF-seeded MWD was significantly 
diminished when compared to that of ad-MVF-seeded MWD on day 14 (Figure 49J).  
 
 
Figure 49. A-F: Intravital fluorescence microscopy (blue light epi-illumination with contrast enhancement by 5 % 
FITC-labeled dextran) of SVF- (A-C) and ad-MVF-seeded (D-F) MWD on day 14 after implantation into full-
thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Dotted lines = matrix 
borders. Arrows = perfused blood vessels. B, E = higher magnifications of inserts in A and D. C, F = higher 
magnifications of inserts in B and E. Scale bars: A, D = 2.4 mm, B, E = 500 µm; C, F = 125 µm. G-J: Fraction of 
perfused ROIs (%) (G, H) and functional microvessel density (cm/cm
2
) (I, J) in the border (G, I) and center zones 
(H, J) of SVF- (white circles, n = 8) and ad-MVF-seeded (black circles, n = 8) MWD on day 0, 3, 6, 10, and 14 
after implantation into full-thickness skin defects within GFP 
-
 C57BL/6 recipient mice, as assessed by intravital 
fluorescence microscopy. Means ± SEM. *p < 0.05 vs. SVF-seeded MWD. 
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The measurement of microhemodynamic parameters revealed that the diameter of individual 
microvessels within border and center zones of both groups decreased over time (Table 5). 
This was associated with an increase of the centerline RBC velocity and wall shear rate 
(Table 5). There were no significant differences of microhemodynamic parameters of 
individual microvessels between SVF- and ad-MVF-seeded matrices throughout the 14-day 
observation period. Trans-illumination stereomicroscopy was used to analyze whether SVF 
single cells or ad-MVF induce hemorrhage formation within the matrices (Figures 50A-F). It 
was shown that bleedings were elevated between day 6 and 10 of microvascular network 
formation. However, no significant differences in hemorrhage formation could be observed 
between SVF- and ad-MVF-seeded MWD (Figure 50G). 
 
 
Figure 50. A-F: Trans-illumination stereomicroscopy of ad-MVF-seeded MWD within the dorsal skinfold chamber 
of GFP
-
 C57BL/6 recipient mice, displaying different manifestations of matrix-induced bleedings according to a 
semi-quantitative hemorrhagic score, i.e. 1: No bleeding (A), 2: 1-25 % (B), 3: 26-50 % (C), 4: 51-75 % (D), 5: 76-
100 % (E), 6: Bleeding exceeding matrix surface (F). Scale bars = 1.3 mm. G: Hemorrhagic score of vehicle- 
(white circles; n = 8) and enox-treated (black circles; n = 8) ad-MVF-seeded MWD, as assessed by trans-
illumination stereomicroscopy. 
 
 d0 d3 d6 d10 d14 
Diameter (µm) 
Matrix border (SVF) - - 32.0 ± 2.6 18.3 ± 1.6 17.6 ± 1.4 
Matrix border (ad-MVF) - - 27.4 ± 3.6 19.2 ± 0.8 17.6 ± 1.9 
Matrix center (SVF) - - 30.6 ± 1.3 23.1 ± 2.9 15.7 ± 1.4 
Matrix center (ad-MVF) - - 21.9 ± 9.9 22.8 ± 1.2 20.4 ± 3.2 
Centerline RBC velocity (µm/s) 
Matrix border (SVF) - - 299.8 ± 102.8        307.8 ± 71.7 657.7 ± 158.2 
Matrix border (ad-MVF) - -  117.6 ± 47.3         284.7 ± 102.7 311.9 ± 51.8 
Matrix center (SVF) - -  133.1 ± 84.1          388.2 ± 67.7 483.7 ± 82.0 
Matrix center (ad-MVF) - - 182.3 ± 121.3        332.9 ± 113.5 309.8 ± 26.2 
Wall shear rate (s
-1
) 
Matrix border (SVF) - - 75.2 ± 23.3          125.1 ± 20.3 291.8 ± 45.8 
Matrix border (ad-MVF) - - 33.1 ± 11.9 116.8 ± 31.6 150.7 ± 31.9 
Matrix center (SVF) - - 35.9 ± 23.6          145.9 ± 33.2 245.7 ± 55.5 
Matrix center (ad-MVF) - - 58.5 ± 17.8 121.3 ± 44.6 130.5 ± 28.9 
 
Table 5. Diameter, centerline RBC velocity, and wall shear rate of individual microvessels within the border and 
center zones of SVF- and ad-MVF-seeded MWD on day 0 (day of implantation) as well as 3, 6, 10, and 14 days 
after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. 
Mean ± SEM. 
*
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At the end of the 2-week observation period, the matrices were histologically and 
immunohistochemically analyzed. HE-stained sections revealed a comparable infiltration of a 
dense vascularized granulation tissue within the border zones of SVF- (3697 ± 373 
cells/mm2) and ad-MVF-seeded (4515 ± 347 cells/mm2) NWD (Figures 51A and C). 
Interestingly, ad-MVF-seeded matrices exhibited a significantly higher number of infiltrated 
single cells within their center zones (3465 ± 433 cells/mm2) when compared to SVF-seeded 
matrices (1884 ± 485 cells/mm2) (Figures 51B and D). 
 
 
Figure 51. A-D: HE-stained sections of SVF- (A, B) and ad-MVF-seeded (C, D) MWD on day 14 after 
implantation into full-thickness skin defects within dorsal skinfold chambers of GFP
-
 C57BL/6 recipient mice. 
Broken lines = matrix. Frames = center zones of the matrices. B, D = higher magnifications of closed frames in A 
and C. Scale bars: A, C = 260 µm; B, D = 40 µm. 
 
Although not proven to be significant, detection of Sirius red-stained sections revealed that 
SVF-seeded MWD contained less mature collagen fibers within its center zones when 
compared to ad-MVF-seeded MWD, indicating an improved incorporation of ad-MVF-seeded 
matrices on day 14 (Figures 52A-D). Immunohistochemical analyses showed a significantly 
higher density of CD31+ microvessels in both border and center zones of ad-MVF-seeded 
MWD when compared to SVF-seeded MWD (Figures 53A-E). 
 
 
Figure 52. A-C: Polarized light microscopy of Sirius red-stained sections of normal skin (A) as well as SVF- (B) 
and ad-MVF-seeded (C) matrices. Scale bars = 25 µm. D: Total collagen ratio (matrix/skin) in the border and 
center zones of SVF- (white bars, n = 8) and ad-MVF-seeded (black bars, n = 8) matrices on day 14, as assessed 
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Of interest, CD31/GFP co-stainings revealed that ~ 90 % of all detected microvessels in the 
center zones of all matrices originated from the seeded GFP+ isolates. Whereas the border 
zones of ad-MVF-seeded matrices also contained > 90 % GFP+ microvessels, only ~ 67 % of 
all microvessels within the border zones of SVF-seeded matrices were GFP+ (Figures 53F-I). 
 
 
Figure 53. A-D: Immunohistochemical detection of CD31
+
 microvessels (arrows) within the border (A, C) and 
center (B, D) zones of SVF- (C, D) and ad-MVF-seeded (A, B) matrices. Scale bars = 25 µm. E: Microvessel 
density (mm
-2
) in the border and center zones of SVF- (white bars, n = 8) and ad-MVF-seeded (black bars, n = 8) 









 microvessels.  
Scale bars = 45 µm. I: GFP 
+
 microvessels (%) within the border and center zones of SVF- (white bars, n = 8) and 
ad-MVF-seeded (black bars, n = 8) MWD. Means ± SEM. *p < 0.05 vs. SVF-seeded MWD. 
 
6.4.3. Epithelialization  
Repetitive stereomicroscopic analyses of the matrices revealed a comparable 
epithelialization of SVF- and ad-MVF-seeded MWD (Figures 54A-G). On day 14 after 
implantation, these findings were further confirmed by the detection of a cytokeratine+ 




Figure 54. A-F: Stereomicroscopic images showing the epithelialization of implanted SVF- (A-C) and ad-MVF-
seeded (D-F) MWD directly (A, D) as well as on day 6 (B, E) and 14 (C, F) after implantation into full-thickness 
skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Scale bars = 1 mm. G: 
Epithelialization (% of total matrix diameter) of SVF- (white bars, n = 8) and ad-MVF-seeded (black bars, n = 8) 
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Figure 55. A, B: Immunohistochemical detection of the cytokeratine
+
 epithelial layer (arrows) covering SVF- (A) 
and ad-MVF-seeded (B) MWD
 
on day 14 after implantation into full-thickness skin defects within dorsal skinfold 
chambers of GFP 
-
 C57BL/6 recipient mice. Scale bars = 300 µm. C: Epithelialization (% of total matrix surface) of 
SVF- (white bars, n = 8) and ad-MVF-seeded (black bars, n = 8) MWD on day 14 after implantation, as assessed 
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6.5. Enox treatment 
6.5.1. Vascularization and tail vein bleeding time 
It is known that LMWHs, such as enox, not only exhibit anti-thrombotic but also anti-
angiogenic properties. This may prevent the interconnection of seeded ad-MVF and/or 
increase the risk of matrix-induced bleeding after implantation of MWD. Accordingly, in this 
experimental section the vascularization of enox- and vehicle-treated ad-MVF-seeded MWD 
was analyzed by means of intravital fluorescence microscopy (Figures 56A-L). On day 3 after 
implantation of enox-treated, ad-MVF-seeded matrices, individual blood-perfused 
microvessels could already be detected, indicating an early interconnection of ad-MVF with 
the surrounding host microvasculature (Figure 56M). In contrast, vehicle-treated, ad-MVF-
seeded MWD did not exhibit blood-perfused microvessels before day 6 after implantation 
(Figure 56M). Throughout the remaining observation days, seeded ad-MVF reassembled into 
newly developing microvascular networks within both matrices (Figures 56M and N). 
Noteworthy, enox-treated matrices exhibited a slightly increased density of these networks, 
as indicated by a significantly higher functional microvessel density on day 10 when 
compared to vehicle-treated controls (Figure 56N). Furthermore, a continuous vascular 
maturation was observed in both groups over time, as characterized by progressively 
decreasing diameters as well as increasing centerline RBC velocities and wall shear rates of 
individual microvessels (Table 6).  
 
 d0 d3 d6 d10 d14 
Diameter (µm) 
Vehicle - - 30.6 ± 6.1 22.5 ± 2.1 17.8 ± 1.6 
Enox - 38.6 ± 5.5         29.0 ± 1.9 19.8 ± 1.2 16.3 ± 1.0 
Centerline RBC velocity (µm/s) 
Vehicle - - 174.7 ± 74.4        440.9 ± 103.7 562.9 ± 111.2 
Enox - 22.5 ± 14.5           299.6 ± 83.7         463.9 ± 14.2   445.9 ± 52.3 
Wall shear rate (s
-1
) 
Vehicle - - 45.8 ± 23.5          156.1 ± 29.1 273.9 ± 67.4 
Enox - 5.5 ± 3.9 82.3 ± 23.6 190.2 ± 10.7 225.1 ± 30.8 
 
Table 6. Diameter (µm), centerline RBC velocity (µm/s), and wall shear rate (s
-1
) of individual microvessels within 
enox- and vehicle-treated (control) ad-MVF-seeded MWD on day 0 (day of implantation) as well as 3, 6, 10 and 
14 days after implantation into dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Mean ± SEM. 
 
To verify the anti-coagulative activity of enox, a tail vein bleeding test was performed at the 
end of the 2-week observation period. As anticipated, the tail vein bleeding time in enox-
treated mice was significantly prolonged when compared to vehicle-treated controls (Figure 
56O). 
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Figure 56. A-L: Intravital fluorescence microscopy (blue light epi-illumination, 5 % FITC-labeled dextran) of 
vehicle- (A-F) and enox-treated (G-L) ad-MVF-seeded MWD
 
on day 0 (A, D, G, J), 6 (B, E, H, K), and 14 (C, F, I, 
L) after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 recipient mice. A-C 
and G-I = overview of the chamber observation window. D-F and J-L = higher magnifications of inserts in A-C and 
G-I. Broken line = matrix border. Arrows = perfused microvessels. Scale bars: A-C and G-I = 2.2 mm, D-F and J-L 
= 500 µm. M, N: Perfused ROIs (%) (M) and functional microvessel density (cm/cm²) (N) of vehicle- (white bars; n 
= 8) and enox-treated (black bars; n = 8) ad-MVF-seeded MWD. Means ± SEM. *p < 0.05 vs. vehicle. O: Tail vein 
bleeding time (s) of vehicle- (white bar; n = 8) and enox-treated (black bar; n = 8) mice, as assessed by the tail 
vein bleeding test. Means ± SEM. *p < 0.05 vs. control. 
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6.5.2. Hemorrhage formation  
Trans-illumination stereomicroscopy was used to analyze whether the anti-coagulative effect 
of enox promotes hemorrhage formation within ad-MVF-seeded matrices (Figures 57A-G). 
The highest hemorrhagic score in both groups could be detected on day 6 (Figures 57B, E, 
and G).  
 
 
Figure 57. A-F: Trans-illumination stereomicroscopy of vehicle- (A-C) and enox-treated (D-F) ad-MVF-seeded 
MWD on day 0 (A, D), 6 (B, E), and 14 (C, F) after implantation into full-thickness skin defects within dorsal 
skinfold chambers of GFP
-
 recipient mice, as assessed by the semi-quantitative hemorrhagic score, i.e. 1: No 
bleeding, 2: 1-25 %, 3: 26-50 %, 4: 51-75 %, 5: 76-100 %, 6: Bleeding exceeding matrix surface. Scale bars = 1.5 
mm. G: Hemorrhagic score of vehicle- (white circles; n = 8) and enox-treated (black circles; n = 8) ad-MVF-
seeded MWD, as assessed by trans-illumination stereomicroscopy. 
 
6.5.3. Incorporation  
In line with the aforementioned in vivo results, further histological analyses revealed a 
comparable incorporation of vehicle- and enox-treated MWD within dorsal skinfold chambers 
of GFP- C57BL/6 recipient mice on day 14 after implantation. Matrices of both groups were 
surrounded by a well-vascularized granulation tissue, which also grew into the pores of the 
matrices´ border zones (Figures 58A-D).   
 
 
Figure 58. A-D: HE-stained sections of vehicle-treated (A, C) and enox-treated (B, D) ad-MVF-seeded MWD on 
day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of GFP 
-
 C57BL/6 
recipient mice. Broken line = matrix border. C and D = higher magnifications of inserts in A and B. Scale bars: A, 
B = 200 µm; C, D = 60 µm.  
*
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Furthermore, both matrices exhibited a comparable number of CD31+ microvessels (~ 140 
mm-2) (Figure 59A-C) as well as a comparable collagen content on day 14 after implantation 
(Figures 59D-G). Additionally, CD31/GFP co-staining revealed that ~ 90 % of the 




Figure 59. A, B: Immunohistochemical detection of CD31 
+
 microvessels (arrows) within vehicle- (A) and enox-
treated (B) MWD on day 14 after implantation into full-thickness skin defects within dorsal skinfold chambers of 
GFP
-
 C57BL/6 recipient mice. Scale bars = 65 µm. C: Microvessel density (mm
-2
) within vehicle- (white bar; n = 8) 
and enox-treated (black bar; n = 8) ad-MVF-seeded MWD, as assessed by immunohistochemical analysis. Means 
± SEM. D-F: Polarized light microscopy of Sirius red-stained sections of normal skin (D) as well as vehicle- (E) 
and enox-treated (F) ad-MVF-seeded MWD. Scale bars = 32 µm. G: Total collagen ratio (matrix/skin) within 









 microvessels. Scale 
bars = 45 µm. K: GFP
+
 microvessels (%) within vehicle- (white bars, n = 8) and enox-treated (black bars, n = 8), 
ad-MVF-seeded MWD. Means ± SEM.  
 
6.5.4. Epithelialization  
Repetitive epi-illumination stereomicroscopy of vehicle- and enox-treated MWD revealed a 
progressing and comparable epithelialization of both vehicle- and enox-treated matrices over 
time (Figures 60A-G). These results were further confirmed by immunohistochemical 
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cytokeratine+ epithelial layer on day 14 after implantation (Figures 61A-C). 
 
 
Figure 60. A-F: Stereomicroscopic images of implanted vehicle- (A-C) and enox-treated (D-F) ad-MVF-seeded 
MWD on day 0 (A, D) as well as on day 6 (B, E) and 14 (C, F) after implantation into full-thickness skin defects 
within dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Scale bars = 750 µm. G: Epithelialization (% of 
total matrix surface) of vehicle- (white bars; n = 8) and enox-treated (black bars; n = 8) ad-MVF-seeded MWD, as 
assessed by planimetric analysis of stereomicroscopic images. Means ± SEM. 
 
 
Figure 61. A, B: Immunohistochemical detection of the cytokeratine
+
 epithelial layer (arrows) covering vehicle- 
(A) and enox-treated (B) ad-MVF-seeded MWD
 
on day 14 after implantation into full-thickness skin defects within 
dorsal skinfold chambers of GFP 
-
 C57BL/6 recipient mice. Scale bars = 330 µm. C: Epithelialization (% of total 
matrix diameter) of vehicle- (white bars; n = 8) and enox-treated (black bars; n = 8) ad-MVF-seeded MWD, as 
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6.6. Summary of the results 
The aim of the present doctoral thesis was to test several hypotheses, which may be of 
crucial importance for the transfer of ad-MVF as prevascularization units into clinical practice.  
 
In a first set of experiments it was tested whether older GFP+ C57BL/6 donor animals 
contain reduced volumes of adipose tissue as well as lower numbers of ad-MVF when 
compared to younger ones. The following results were found: 
 Older donor mice did not contain reduced volume of adipose tissue when compared 
to younger ones. 
 Older donor mice did not contain reduced numbers of ad-MVF when compared to 
younger ones. 
 Ad-MVF isolated from 7 - 12 months old donor mice exhibit both a comparable 
cellular composition and length distribution. 
 
In a second set of experiments it was first tested whether the difference in MWD and FWM 
sample preparation leads to variations in their fiber thicknesses, fiber lengths, or pore sizes. 
Moreover, it was tested whether a more homogeneous seeding of ad-MVF into FWM is 
possible and leads to an improved matrix vascularization and incorporation when compared 
to ad-MVF-seeded MWD. The following results were found: 
 The preparation of FWM does not lead to different pore sizes, fiber thicknesses, or 
fiber lengths when compared to MWD. 
 FWM allows a more homogeneous distribution of ad-MVF during sample preparation 
when compared to MWD.  
 The more homogeneous distribution of ad-MVF within FWM leads to a reduced 
vascularization and incorporation when compared to ad-MVF-seeded MWD. 
 
In a third set of experiments it was tested whether the seeding density of ad-MVF is a 
crucial determinant for the adequate vascularization and incorporation of matrices. The 
following results were found: 
 The least required density of ad-MVF to guarantee an adequate matrix 
vascularization and incorporation is 80,000 ad-MVF/cm2. 
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 MWD seeded with less than 80,000 ad-MVF/cm2 exhibits a reduced oxygenation on 
day 14 after implantation into full-thickness skin defects within dorsal skinfold 
chambers of GFP- C57BL/6 recipient mice. 
 
In a fourth set of experiments it was tested whether the novel approach of ad-MVF-based 
prevascularization is superior to the prevascularization with the SVF. The following results 
were found: 
 Freshly isolated ad-MVF exhibit a significantly higher viability when compared to SVF 
single cells. 
 Ad-MVF-seeded MWD exhibits a better vascularization and incorporation when 
compared to SVF-seeded MWD. 
 
In a fifth set of experiments it was tested whether the anti-angiogenic and anti-coagulative 
properties of enox lead to a reduced interconnection of ad-MVF and/or increased matrix-
induced bleeding. The following results were found: 
 The anti-angiogenic properties of enox do not lead to a reduced vascularization within 
ad-MVF-seeded MWD. 
 The anti-coagulative properties of enox do not promote increased hemorrhage 












7.1. Discussion of materials and methods 
7.1.1. Dorsal skinfold chamber model 
In 1928, the first observation chamber was implanted into the ears of rabbits to study the 
behavior of living cells by means of intravital microscopy [SANDISON, 1928]. The transparent 
chamber model was then adapted for its use in mice in 1943 [ALGIRE et al., 1943]. This 
particularly allowed analyses of both growth and vascularization of implanted tumors [ALGIRE 
et al., 1943]. However, newly formed granulation tissue impaired the analysis of the 
physiological microvasculature [ALGIRE et al., 1943]. After the chamber model was 
continuously modified, it has been widely used for the analysis of the microcirculation over 
the past decades [LEHR et al., 1993; USHIYAMA et al., 2004; CONTALDO et al., 2007; DEBERGH 
et al., 2010; LASCHKE et al., 2011; SCKELL and LEUNIG, 2016]. The dorsal skinfold chamber 
model bears the advantage that the chamber window can be horizontally placed under a 
microscope for repetitive and non-invasive intravital microscopy in trans-illumination or epi-
illumination [LASCHKE and MENGER, 2016]. In addition, since the cover glass of the chamber 
can temporarily be removed, the dorsal skinfold chamber model is a perfect tool for the 
chronic observation of implanted biomaterials and tissue constructs. However, to assure an 
air-free closure of the chamber, the size of the matrices should not exceed ~ 3 x 3 x 1 mm 
[LASCHKE and MENGER, 2016]. This size is not comparable to the size of biomaterials usually 
implanted into patients in clinical practice. Nontheless, the experimental setting of the dorsal 
skinfold chamber model allows for the in vivo observation of matrix vascularization under 
highly standardized conditions.  
 
Despite all benefits of the dorsal skinfold chamber model, complications may appear 
throughout the observation period of 2 weeks. Although the titanium chamber is designed 
with a relatively low weight of ~ 4 g, it may progressively subside laterally over time. Hence, 
in the present work, some of the created full-thickness skin defects changed their location 
within the observation window over time, eventually moving from their well-observable 
central position (Figure 62A) to an only partly observable position underneath the snap ring 
(Figure 62B). In such a case, the snap ring was removed before the microscopic imaging. 
Accordingly, microscopic epi- and transillumination microscopy of all implanted matrices 
could be conducted throughout the 14-day observation period.  
 
Besides the dislocation of implanted matrices, the formation of hemorrhages could be 
observed throughout the experiments. Noteworthy, appearance and severity of the bleeding 
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correlated with the formation of microvascular networks within the implanted matrices. 
Particularly during the early stage of the vascularization process, when individual ad-MVF 
interconnected with each other or the blood vessels of the surrounding host tissue, matrix-
induced bleeding complicated the detection of newly epithelialized areas during epi-
illumination microscopy (Figure 62C). This was due to the rather incomplete and immature 
microvascular networks, leading to a leakage of blood particularly around day 6 after 
implantation of the matrices into the full-thickness skin defects. Since, for these reasons, epi-
illumination was not always sufficient to detect the epithelial layer, trans-illumination had to 
be additionally used. Noteworthy, the combination of epi- and trans-illumination microscopy 
allowed the detection of epithelial layers at every time point of the 2-week observation period, 
regardless of the bleeding severity. 
 
 
Figure 62. A: Full-thickness skin defect filled with MWD in the center of the observation window on day 14 after 
implantation, allowing an unproblematic detection of epithelialization. B: Dislocated wound on day 14, partially 
covered by the snap ring. C: Severe bleeding of the wound on day 6 after implantation. D: Ingrowth of hair into 
the dorsal skinfold chamber on day 14 after implantation. Scale bars: A-C = 1.9 mm; D = 1.3 mm.   
 
For all in vivo experiments, dorsal skinfold chambers were implanted into C57BL/6 mice, one 
of the most used mouse strains for experimental studies [MARIN-BAÑASCO et al., 2014]. 
However, this strain is also known to exhibit skin pigmentations due to the accumulation of 
melanin [VAN DER HEIJDEN et al., 1995; PLONKA et al., 2005]. The appearance of “black spots” 
[WEISSMAN, 1967] within the animals´ skin is unpredictable and can only be detected after 
depilation. Since hair and melanin lead to a thicker skin, the fluorescent signal within the 
microvascular network may not, or only partly, be detected. Hence, this may impair the 
imaging quality of intravital fluorescence microscopy. Accordingly, animals that entered the in 
vivo experiments of the present thesis had to be carefully selected. Only mice without 
pigmented skin (Figures 63A and B) were used for the implantation of dorsal skinfold 
chambers. However, mice showing only little amounts of pigmented skin could still be used 
when the estimated position of the observation window was guaranteed within a non-
pigmented area (Figures 63C and D). This selection of mice guaranteed a consistently 
sufficient intravital fluorescence microscopic imaging quality and prevented a loss of data 
throughout the entire observation period. Of interest, skin abnormalities were not always 
obvious. Although skin appeared to be “normal” after depilation, an increased growth rate of 
hair could sometimes be observed (Figure 62D). This, however, did not hinder a straight-
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forward workflow or cause a loss of data. In fact, the detection of newly epithelialized areas 
by means of epi-illumination as well as the detection of hemorrhages by means of trans-
illumination could still be performed with no limitations. 
 
 
Figure 63. A: C57BL/6 mouse exhibiting normal skin without pigmentation. Circle = estimated position of the 
observation window after dorsal skinfold chamber implantation. Scale bar = 12 mm. B: Higher magnification of the 
skin, showing no pigmentation. Scale bar = 6 mm. C: C57BL/6 mouse exhibiting pigmented skin. Circle = 
estimated position of the observation window after dorsal skinfold chamber implantation. Arrows = pigmented 
areas of the skin. Scale bar = 10 mm. D: Higher magnification of the skin, showing a strong pigmentation. Scale 
bar = 6 mm. 
 
 
7.1.2. Intravital fluorescence microscopy 
Intravital fluorescence microscopy is a widely used method to study the microcirculation and 
to assess microhemodynamic parameters by visualizing the blood flow (Figure 64) via the 
injection of fluorescent dyes [VAJKOCZY et al., 1998; STEINBAUER et al., 2000; BARON et al., 
2011; BOULAFTALI et al., 2012]. Moreover, this method allows a repetitive detection and, 
hence, represents an ideal approach to observe dynamic processes, such as angiogenesis. 
In combination with image processing techniques, this approach allows the recording of 
microscopic images and videos, which can easily be evaluated at the end of the experiments 
without any additional stress for the animals. However, a too long exposure time to light 
excitation can still lead to damage of the visualized tissue, caused by the induction of oxygen 
radicals [KONTOS et al., 1983]. Consequences of such phototoxic effects on the 
microcirculation can be an increased activation of platelets with thrombus formation 
[HERRMANN, 1983], damage of endothelial cells leading to an increased permeability of the 
vessel wall [KONTOS et al., 1983], vasospasms [SAETZLER et al., 1997], increased leukocyte-
endothelial cell interactions [SAETZLER et al., 1997], or the reduction of the functional 
microvessel density [FRIESENECKER et al., 1994]. Of interest, as shown in previous studies in 
A B
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hamster dorsal skinfold chambers [STEINBAUER et al., 2000], such effects can be avoided by 
keeping the exposure time of the analyzed tissue to light excitation to a minimum of ~ 15 - 20 
minutes. In the present work, this time limit was not exceeded. 
 
 
Figure 64. Intravital fluorescence microscopic image of ad-MVF-seeded MWD on day 10 after implantation into a 
full-thickness skin defect within a dorsal skinfold chamber of a GFP
-
 C57BL/6 recipient mouse. Black line = matrix 
border. Asterisks = newly developing epithelial layer. Broken line = edge of the epithelial layer. Arrow = newly 
developed blood-perfused vessel. Scale bar = 250 µm. 
 
 
7.2. Discussion of the results 
7.2.1. Ad-MVF characterization 
Ad-MVF have previously been described as biologically intact vascularization units that can 
be used for the prevascularization of matrices [FRUEH et al., 2016]. Of interest, studies have 
also shown that network formation and vascular remodeling are markedly affected in 
implanted matrices, which were seeded with ad-MVF from aged donors when compared to 
younger ones [LASCHKE et al., 2014]. Therefore, in the first set of experiments it was 
hypothesized that older mice also contain reduced volumes of adipose tissue as well as 
lower numbers of ad-MVF when compared to younger animals. However, it could be 
demonstrated that mice between the age of 7 - 12 months exhibited a comparable volume of 
adipose tissue as well as a comparable number of ad-MVF isolated from 1 mL adipose 
tissue. Furthermore, the average length of fragments was found to be ~ 38 µm in all age 
groups. Moreover, the analysis of length distribution of ad-MVF revealed that ~ 70 % of all 
counted ad-MVF exhibited a length of 21 – 50 µm. These results indicate that the age of the 
donor animal does not affect the outcome of ad-MVF isolation. Further flow cytometric 
analyses also showed a comparable cellular composition of ad-MVF from the donor mice of 






D i s c u s s i o n  | 72 
 
expressed the stem cell surface markers CD90 and CD177. Particularly the latter ones have 
been reported to exhibit a high regenerative and angiogenic potential [LI et al., 2003; LI et al., 
2005; OISHI and ITO-DUFROS, 2006]. Taken together it can be concluded that the available 
volume of donor fat as well as the composition of isolated ad-MVF is identical when 
harvested from animals of the tested age range. Hence, it can be assumed that the seeding 
of MWD or FWM with ad-MVF isolated from donor mice within the age range of 7 - 12 
months can be conducted in a very standardized manner. 
 
7.2.2. MWD vs. FWM 
In clinical practice, MWD represents a well-established dermal substitute for the filling of full-
thickness skin defects. More recently, Integra Life Sciences has also developed the 
injectable FWM, which is especially suitable for the treatment of complex skin defects, such 
as tunneling wounds with anomalous geometries [CAMPITIELLO et al., 2015]. However, there 
is a lack of preclinical studies comparing the in vitro and in vivo properties of these matrices, 
which should exhibit an identical material composition. For this reason, the aim of the 
second set of experiments was to clarify whether MWD and FWM exhibit different pore 
sizes and surface topographies due to their differences in sample preparation. Of interest, in 
vitro analyses of both materials revealed an average inter-fiber distance of ~ 45 µm. This 
may be particularly indicated for the regeneration of skin defects. In fact, CHOI et al. [2013] 
showed that matrices with small pores < 200 µm are known to support the development of 
dense vascular networks with small vessels and poor penetration depth, as found in skin 
under physiological conditions. Fiber diameter and fiber length were comparable in both 
matrices as well. These findings indicate that the varying sample preparation of both 
matrices does not alter their structural properties. However, scanning electron microscopy 
revealed that the surface topography differed between MWD and FWM. FWM presented an 
irregular and fissured surface when compared to the more planar surface of the sheet-like 
MWD. This was most likely due to the fact that the gel-like consistency of FWM did not allow 
this matrix to keep a stable form. This difference in the consistency between MWD and FWM 
may markedly affect the porous architecture of both materials after their press-fit implantation 
into full-thickness skin defects, resulting in different biological host tissue responses after 
implantation. 
 
To test this, non-seeded MWD and FWM were next implanted into full-thickness skin defects 
within dorsal skinfold chambers of C57BL/6 recipient mice. Epi-illumination light microscopy 
revealed a comparable epithelialization of both matrices over time. In addition, it could be 
demonstrated that vascularized tissue progressively grew into the pores of MWD and FWM. 
Of interest, a dense granulation tissue could exclusively be detected within the border zones 
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of both matrices at the end of the 2-week observation period. Additionally, both matrices 
exhibited a comparably low microvessel density and collagen ratio, indicating a rather slow 
incorporation. These rather negative findings should be interpreted with caution when it 
comes to the application of the matrices in clinical practice. In fact, based on their skin 
anatomies, there are major distinctions between the healing mechanisms and kinetics of 
wounds in mice and humans [LINDBLAD, 2008; RITTIÉ, 2016]. For example, human skin 
exhibits a much thicker epidermis and a higher vascularization when compared to the skin of 
mice. Hence, the results of this experimental section may not directly reflect the incorporation 
of MWD and FWM in human wounds.  
 
The implantation of biomaterials, such as MWD or FWM, usually causes a foreign body 
reaction, which is associated with the infiltration of various immune cells [ANDERSON et al., 
2008]. Particularly in the initial phase, activated polymorphonuclear leukocytes and 
macrophages are recruited from the blood stream to release numerous cytokines and growth 
factors at the site of implantation [GARASH et al., 2016]. Noteworthy, this process is similar to 
the inflammatory phase of wound healing [REINKE and SORG, 2012]. Hence, the inflammatory 
tissue response to MWD and FWM was analyzed as an indicator of both matrices´ 
biocompatibility, which is defined as “the ability of a material to perform with an appropriate 
host response in a specific application” [VAN WACHEM et al., 1994; RATNER, 2011]. During the 
initial phase of implantation, it could be demonstrated that the matrices were not only 
primarily infiltrated by neutrophilic granulocytes but also macrophages and lymphocytes. 
However, there were no significant differences between the two matrices, indicating a 
comparable in vivo biocompatibility.  
 
Taken together, the first part of this second section did not reveal significant differences in 
the in vivo performances of MWD and FWM in a standardized wound healing model. 
Although these findings indicate that both matrices may be equally suitable for clinical use, 
the injectable FWM may pave the way for innovative concepts in the area of tissue 
engineering and regenerative medicine by allowing a more homogeneous incorporation and 
distribution of bioactive molecules and cells within this gel-like material. 
 
Previous studies have shown that ad-MVF are mainly trapped in the surface layers of MWD 
[FRUEH et al., 2016]. In this experimental section it was further hypothesized that a more 
homogeneous distribution of ad-MVF may be possible within FWM due to its differing sample 
preparation and, hence, lead to an improved matrix vascularization and incorporation. In a 
first in vitro analysis it was confirmed that ad-MVF could be distributed more homogeneously 
within FWM when compared to MWD. However, this did not result in an improved 
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vascularization and incorporation after implantation into full-thickness skin defects within 
dorsal skinfold chambers of GFP- C57BL/6 recipient mice. This was most likely caused by an 
elevated distance between individual fragments. Actually, both matrices were seeded with a 
comparable number of ~ 15,000 ad-MVF. Accordingly, the more homogeneous distribution of 
individual ad-MVF within FWM was associated with a ~ 15-fold higher inter-fragment 
distance. Hence, individual ad-MVF needed more time to bridge the wider distances between 
each other. This, in turn, prolonged the process of reassembly into newly developing 
microvascular networks. Accordingly, when compared to FWM, the blood perfusion of ad-
MVF-seeded MWD was sped up and improved in the early stage after implantation, as 
indicated by a higher centerline RBC velocity and wall shear rate of individual microvessels. 
This could have resulted in an increased survival rate of individual ad-MVF. In accordance 
with this view, MWD showed a diminished number of apoptotic cells on day 6 as well as a 
lower fraction of CD31+/GFP+ microvessels at the end of the 2-week observation period. 
Ultimately, histological and immunohistochemical analyses revealed that most pores of ad-
MVF-seeded MWD were filled with a densely vascularized granulation tissue at the end of 
the in vivo observation period, indicating a good matrix incorporation into the surrounding 
host tissue. This was further confirmed by an increased proliferation rate and collagen 
content as well as an accelerated epithelialization over time when compared to ad-MVF-
seeded FWM. Taken together, these findings demonstrate that a locally limited and high 
seeding density of ad-MVF is already sufficient to achieve a rapid matrix vascularization.  
 
Lastly, it may be assumed that it is possible to further improve the vascularization of FWM by 
means of seeding an increased number of ad-MVF. This, in turn, may shorten the distance 
between individual ad-MVF and, thus, allow them to rapidly reassemble into microvascular 
networks. However, for this the needed volume of donor fat tissue may not always be 
available in patients. Therefore, ad-MVF-seeded FWM may be specifically recommended as 
an injectable carrier for the filling of small and hardly to access wounds with anomalous and 
irregular geometries, for which relatively low amounts of donor fat tissue would be necessary. 
In contrast, ad-MVF-seeded MWD may rather serve for the coverage of large skin defects, 
such as caused by extensive burns. 
 
7.2.3. Ad-MVF seeding density 
In this third set of experiments it was hypothesized that the seeding density of ad-MVF is a 
crucial determinant for the adequate vascularization and incorporation of matrices. To test 
this, MWD was seeded with three different densities of ad-MVF and implanted into full-
thickness skin defects of GFP- C57BL/6 recipient mice. Noteworthy, the seeding of ~ 120,000 
ad-MVF/cm2 MWD has been previously shown to be sufficient for an adequate matrix 
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vascularization and incorporation [FRUEH et al., 2017]. This density corresponded to the 
density of the HD ad-MVF-seeded control group of this experimental section.  
 
Especially in case of severe burn injuries affecting large surface areas of the body [SUPP and 
BOYCE, 2005], the available amount of adipose donor tissue for the isolation of ad-MVF may 
be limited. Taking this into account, the findings of this third set of experiments show that 
only ~ 80,000 ad-MVF/cm2 MWD, corresponding to the MD group, are needed to assure a 
sufficient vascularization and incorporation. In contrast, reducing the number of ad-MVF to 
only ~ 40,000/cm2 MWD, corresponding to the LD group, results in an insufficient matrix 
vascularization and incorporation, as indicated by the lack of a vascularized granulation 
tissue within the center zones of the matrices. Using intravital fluorescence microscopy, it 
was further demonstrated that HD- and MD-seeded MWD exhibit a comparable 
vascularization over time, whereas LD ad-MVF-seeded MWD is characterized by a 
significantly reduced number of perfused ROIs and a reduced microvessel density. In 
addition, photoacoustic analyses revealed lower O2 levels within LD ad-MVF-seeded MWD 
on day 14 after implantation. This reduced oxygenation, in turn, may lead to an impaired 
engraftment of STSG under clinical conditions.  
 
The process of ad-MVF reassembly not only includes the interconnection of single ad-MVF 
with each other but also the development of anastomoses with the blood vessels of the 
surrounding host tissue. The latter mechanism leads to an early onset of blood perfusion, 
while newly developing microvascular networks within the matrices have not been fully 
established yet and, thus, allow an increased leakage of blood. Accordingly, hemorrhages 
could be found within the matrices of all three groups, mostly pronounced between day 6 and 
10 after implantation. Moreover, the delayed onset of blood perfusion in LD ad-MVF-seeded 
MWD was associated with less bleedings on day 6. Noteworthy, the extent of hemorrhages 
in all experimental groups decreased again towards day 14. This can be explained by the 
continuous stabilization of the newly developing microvascular networks, as indicated by 
decreased vessel diameters as well as elevated centerline RBC velocities and wall shear 
rates of individual microvessels.  
 
Immunohistochemical analyses revealed that the pores in the center of both HD and MD ad-
MVF-seeded matrices were filled with a vascularized granulation tissue. LD ad-MVF-seeded 
matrices, on the other hand, mainly contained infiltrated single cells. As anticipated, LD ad-
MVF-seeded matrices further showed a significantly reduced density of CD31+ microvessels. 
However, the fraction of GFP+ microvessels was comparable in all three groups, indicating 
that even in the poorly vascularized LD group ad-MVF survived throughout the observation 
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period of 14 days. The overall correlation between a low ad-MVF seeding density and a 
reduced ingrowth of blood vessels may be explained by decreased levels of pro-angiogenic 
factors, such as VEGF and bFGF, within the matrices. Previous studies have shown that 
isolated ad-MVF release relevant amounts of these factors, which considerably participate to 
the high angiogenic activity of ad-MVF after in vivo implantation [LASCHKE et al., 2012]. In this 
context, it should also be taken into account that there is a close connection between 
angiogenesis and inflammation [FIEDLER et al., 2006; DIPIETRO, 2016]. Pro-angiogenic 
factors are capable of acting as chemokines for the recruitment of immune cells [KHOURY and 
ZIYADEH, 2011; BARBAY et al., 2015]. Accordingly, histological analyses revealed comparable 
numbers of MPO+ neutrophilic granulocytes, CD68+ macrophages, and CD3+ lymphocytes in 
HD and MD ad-MVF-seeded MWD. Since immune cell infiltration is a key event in wound 
healing [REINKE and SORG, 2012] and adequate matrix integration [ANDERSON et al., 2008], 
this may have further contributed to the improved incorporation of HD and MD ad-MVF-
seeded MWD, which ultimately showed a higher collagen content and an increased surface 
epithelialization when compared to LD ad-MVF-seeded MWD. 
 
Taken together, this third set of experiments demonstrates that a reduction from ~ 120,000 to 
~ 80,000 ad-MVF/cm2 MWD does not alter the vascularization and incorporation of the matrix 
after implantation into full-thickness skin defects. These novel findings demonstrate that 33 
% less adipose tissue are needed for the isolation of ad-MVF required for a quick and 
adequate vascularization of MWD. Under clinical conditions, this may be especially important 
for the treatment of patients with extensive skin defects and/or limited availability of adipose 
tissue. 
 
7.2.4. Ad-MVF vs. SVF single cells 
Besides the herein described novel ad-MVF-based approach, another common 
prevascularization strategy is the seeding of SVF single cells, which represent a 
heterogeneous mixture of endothelial cells, pericytes, smooth muscle cells, and various stem 
cells [BOURIN et al., 2013; HASSAN et al., 2014; MAIJUB et al., 2015; CERINO et al., 2017; 
LOCKHART et al., 2017]. Of interest, such a SVF single cell-based prevascularization is 
already evaluated in clinical trials for the regeneration of bone fractures or the treatment of 
idiopathic pulmonary fibrosis [TZOUVELEKIS et al., 2013; CHARLES-DE-SÁ et al., 2015; RIGOTTI 
et al., 2016; SAXER et al., 2016]. However, after their seeding onto matrices, SVF single cells 
form a microvasculature de novo by reassembling into new blood vessels. In contrast, the 
fully functional ad-MVF rapidly interconnect to each other or the surrounding host tissue, 
leading to a rapid creation of new vascular networks. Accordingly, it was hypothesized that 
the ad-MVF-based prevascularization is superior to the prevascularization with the SVF. To 
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test this hypothesis, identical amounts of adipose tissue were used for the isolation of both 
ad-MVF and SVF single cells to ensure an identical cell load per matrix, and, thus to 
guarantee a standardized comparison of the vascularization potential between the SVF and 
ad-MVF. However, a longer enzymatic digestion time was needed for the disassembly of fat 
tissue into SVF single cells. Hence, the longer exposure of the tissue to collagenase could 
explain the reduced cell viability of SVF single cells when compared to ad-MVF. These 
results are in line with previous studies, indicating a ranging viability of SVF single cells 
between 80 - 83 % [DOI et al., 2013; PRINS et al., 2016].    
 
Of interest, commercially available devices for the separation of the SVF from lipoaspirates 
exhibit a great heterogeneity regarding the outcome of the isolates´ cellular composition 
[ARONOWITZ and ELLENHORN, 2013]. In contrast, flow cytometric analyses of this 
experimental section revealed that the SVF and ad-MVF are comparable mixtures of 
endothelial cells, perivascular cells, adipocytes, and stem cells. Although this heterogeneous 
composition may complicate the standardization of the method for a broad clinical 
application, it also bears a major advantage. Unlike purified cell isolations, the isolation of the 
SVF and ad-MVF is not associated with any complex cell separation or manipulative 
cultivation steps, which may facilitate the fulfillment of regulatory criteria for clinical approval.  
 
For in vivo analyses, ad-MVF and SVF-seeded MWD were implanted into full-thickness skin 
defects within dorsal skinfold chambers of GFP- C57BL/6 mice to analyze their 
vascularization and incorporation. Of interest, both matrices already exhibited first blood-
perfused microvessels on day 6 after implantation. At this time point, hemorrhage formation 
was mostly pronounced, probably caused by an increased leakage of blood from immature 
microvessels. As a typical sign of microvascular maturation, the diameter of these 
microvessels decreased over time while their centerline RBC velocity and wall shear rate 
increased. Although these characteristics did not differ between both groups, a significantly 
higher number of perfused ROIs and a higher functional microvessel density were found in 
the border zones of ad-MVF-seeded MWD. This can be explained by the fact that ad-MVF 
already represent fully functional arteriolar, capillary, and venular segments that develop 
interconnections with each other and the surrounding microvasculature of the host tissue via 
the process of inosculation to establish a rapid blood perfusion within the implants [FRUEH et 
al., 2017]. In contrast, KOH et al. [2011] showed that the endothelial cells within SVF 
suspensions first reassemble into new vessel channels as a precondition for the subsequent 
formation of microvascular networks. Accordingly, much more time is required to complete 
this process when compared to the ad-MVF-based vascularization. In this context it should 
be further noted that ad-MVF exhibit a length of up to 150 µm [SPÄTER et al., 2017] enabling 
D i s c u s s i o n  | 78 
 
the direct bridging of rather wide distances within tissue constructs in a short period. 
Accordingly, ad-MVF promote a more homogeneous blood perfusion within the border and 
center zones of implanted matrices. Of interest, the difference in vascularization between the 
SVF and ad-MVF group was most pronounced in the center of the implants, where > 90 % of 
all detected microvessels originated from the seeded GFP+ SVF or ad-MVF. UTZINGER et al. 
[2015] showed that the physiological growth rate of microvessels is ~ 5 µm/h. Hence, host 
vessels are mainly expected to occur in the border zones of the matrices. In these regions, 
SVF- and ad-MVF-seeded matrices contained a fraction of ~ 30 % and ~ 10 % GFP- 
microvessels, respectively. Since the detected microvessel density within ad-MVF-seeded 
matrices was ~ 3-fold higher, these immunohistochemical findings demonstrate a 
comparable number of ingrowing GFP- microvessels from the surrounding host tissue into 
both implant types. The epithelialization of both matrices was also found to be comparable. 
This may be explained by the fact, that both SVF- and ad-MVF-seeded matrices initially 
contained an identical cellular load and composition, leading to a comparable release of 
growth factors, which stimulated the vascularization-independent coverage with ingrowing 
keratinocytes from the edges of the wound. 
 
Taken together, the findings of this fourth experimental section demonstrate several 
important advantages of ad-MVF for the prevascularization of matrices when compared to 
the SVF. The faster isolation of ad-MVF may allow their application in a less time-consuming 
intra-operative procedure while exhibiting a higher viability due the shorter enzymatic 
digestion time. This, in turn, may markedly contribute to an enhanced cell yield and, thus, to 
reduced volumes of adipose tissue needed for individual patient treatments. Finally, ad-MVF  
already represent fully functional vessel segments that markedly accelerate and improve the 
vascularization of matrices. In conclusion, all these unique features of ad-MVF suggest their 
future clinical use as vascularization units in tissue engineering.  
 
7.2.5. Enox treatment 
Enox is a frequently used LMWH for the thromboprophylactic therapy of hospitalized 
patients. Of interest, enox not only exerts anti-coagulative effects but also anti-angiogenic 
activity. In fact, enox has been shown to inhibit endothelial cell proliferation, sprouting, and 
tube formation in vitro [MARCHETTI et al., 2008; MOUSA, 2013]. In vivo, enox suppresses 
blood vessel formation in the chorioallantois membrane model [DOGAN et al., 2011; MOUSA, 
2013] and tumor angiogenesis [DEBERGH et al., 2015]. Based on these findings it was herein 
speculated that enox treatment may also prevent the sprouting and reassembly of individual 
ad-MVF into microvascular networks. However, it could be demonstrated that enox even 
promoted the vascularization of ad-MVF-seeded MWD, as indicated by a significantly higher 
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functional microvessel density on day 10 when compared to vehicle-treated controls. A 
reason for this observation could be the anti-coagulative effect of enox, which may prevent 
microthrombosis formation caused by ischemia and reperfusion-induced endothelial cell 
activation of ad-MVF. This prevention of thrombus formation could also be the reason why 
the onset of blood perfusion within the newly developed microvasculature was accelerated. 
Blood-perfused microvessels could already be detected within enox-treated, ad-MVF-seeded 
MWD on day 3 after implantation. In contrast, matrices in vehicle-treated animals did not 
show blood perfusion before day 6.  
 
A successful coverage of full-thickness skin defects not only depends on a sufficient 
vascularization, but also on an intact vessel integrity of the graft bed. Accordingly, hematoma 
and seroma formation beneath the wound bed are common reasons for graft failure [BLUME 
et al., 2010]. To evaluate implant-induced bleeding, a hemorrhagic score was assessed. 
However, even though increased bleeding has been reported as a major side effect of 
LMWH treatment in patients, it was shown that the extent of bleeding in enox-treated 
matrices did not differ from that of vehicle-treated control matrices [NIEUWENHUIS et al., 1999; 
MARTEL et al., 2005]. These results show that enox-treatment does not increase the risk of 
bleeding caused by ad-MVF-seeded MWD, excluding the possibility for hematoma-caused 
graft failure. 
 
As previously described, there is a correlation between the vascularization of implanted 
MWD within full-thickness skin defects and its incorporation into the surrounding host tissue 
[FRUEH et al., 2017]. This incorporation was herein evaluated by the development of a 
vascularized granulation tissue, the formation of collagen fibers, and epithelialization over 
time. In line with the finding that matrices in enox- and vehicle-treated animals exhibited a 
comparable microvessel density, this experimental section showed that none of the above 
listed processes showed significant differences between the two experimental groups.  
 
Taken together, this experimental section shows that enox-treatment does neither alter 
vascularization nor hemorrhage formation within ad-MVF-seeded MWD. Hence, it can be 
summarized that ad-MVF may also be used as vascularization units for dermal skin 
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7.3. Conclusion and clinical perspectives 
The aim of the present doctoral thesis was to test several hypotheses, which are of crucial 
importance for transferring the novel approach of ad-MVF-based matrix prevascularization 
into clinical practice. The results shown in this work strongly indicate the high regenerative 
potential of ad-MVF over single cell-based approaches for future tissue engineering 
strategies [SPÄTER et al., 2017a; 2017b; 2018a; 2018b]. After their seeding onto MWD, ad-
MVF, which represent fully functional vessel segments, are able to interconnect with each 
other as well as with the microvasculature of the surrounding host tissue, resulting in a rapid 
formation of blood-perfused networks. 
 
In future studies it may be very interesting to analyze the vascularization potential of human 
ad-MVF. This could be done by isolating ad-MVF from liposuctioned adipose tissue of 
patients. The isolated ad-MVF could then be seeded onto MWD and subsequently be 
implanted into full-thickness skin defects within immunodeficient mice to analyze the 
vascularization and incorporation of the seeded matrix without the risk of rejection.  
 
Besides the possible use of ad-MVF as prevascularization units for dermal substitutes, these 
vessel segments may also be suitable for the prevascularization of other implants, constructs 
or tissues. For example, ad-MVF may be injected into fracture gaps to enhance bone healing 
or to prevent the development of non-unions, i.e. the permanent failure of broken bones to 
heal without surgical intervention. Moreover, ad-MVF may be used for the prevascularization 
of spheroids, which represent three-dimensional cell clusters that are generated by cellular 
self-assembly in vitro. Of interest, when compared to two-dimensional single cell 
approaches, spheroids exhibit increased proliferation activity, enhanced cellular viability, and 
improved physiological metabolic functions [LASCHKE and MENGER, 2017]. Due to these 
advantages, spheroids are increasingly used as building blocks in tissue engineering and 
regenerative medicine. Since the cells in the core of spheroids are typically exposed to 
hypoxic conditions [PEDRAZA et al., 2011], it may be an advantage to prevascularize the 
spheroids with ad-MVF prior to their in vivo implantation. This could lead to an improved 
cellular survival rate, especially within their core areas. 
 
Taken together, the present doctoral thesis demonstrates the high vascularization capacity of 
ad-MVF within an experimental mouse model. Additional translational studies should now be 
conducted to further pave the way for these promising prevascularization units into clinical 
practice. 
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